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ABSTRACT 
 
Toll-like Receptors (TLRs) represent a class of pattern recognition receptors that 
function to recognize invading microbes and initiate pro-inflammatory responses.  TLR10 is the 
only remaining orphan member of the human TLR family.  Given the established role of TLR 
signaling in both the innate and adaptive arms of immune defense, defining the function of 
TLR10 in the immune response would fill a significant knowledge gap regarding the question of 
why the gene has been propagated through evolutionary history.  Additionally, given the 
growing recognition of the impact of TLR biology on human disease, additional knowledge of 
this orphan TLR may also provide a novel therapeutic target. 
Chapter One of this dissertation introduces the main events that occur in the innate and 
adaptive immune responses to infection and describes the role of TLRs in the induction and 
propagation of such responses.  It also highlights the growing recognition of lymphocyte-
intrinsic TLR signaling and its role in robust adaptive immune responses.  Lastly, it provides 
background information on what is known about TLR10 currently and identifies the knowledge 
gap that this research seeks to fill. 
Chapter Two describes the capacity of TLR10 to act as a general suppressor of pro-
inflammatory TLR signaling.  Given the lack of TLR10 expression in mice, heterologous 
expression of TLR10 in cell lines and transgenic mice was used, and these studies revealed an 
inhibitory role for TLR10 in the context of pro-inflammatory cellular responses to numerous TLR 
ligands.  The effect of TLR10 in abrogating both MyD88 and TRIF dependent signaling was 
discovered using transient transfection techniques.  Lastly, ligation of cell surface TLR10 in 
whole blood using a monoclonal antibody resulted in strongly attenuated responses to TLR 
agonists (Jiang et al. 2016). 
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Chapter Three focuses on the expression of surface TLR10 within the B cell lineage.  
While numerous studies have shown the presence of TLR10 mRNA in cell lines and primary cells, 
the lack of a reliable commercially available antibody to TLR10 prevented careful investigation of 
cell surface expression of TLR10 protein.  A monoclonal antibody created in the lab was used to 
investigate the regulation of TLR10 expression in blood leukocytes and tonsillar tissue.  This led 
to the validation that significant levels of TLR10 are present on CD19+ B cells and that this 
surface expression is attenuated along progressive stages of B cell activation within lymphoid 
tissue. 
Chapter Four presents studies investigating the role of TLR10 in the context of B cell 
activation.  I found that stimulation of TLR10 in human peripheral blood B cells results in 
strongly attenuated B cell proliferation, cytokine production, and induction of B cell activation 
genes.  Additionally, I observed a subtle effect on B cell signaling events via phosphorylation of B 
cell signaling molecules.  These findings are further corroborated with concurrent transgenic 
mouse studies that reveal profound suppressive effects of TLR10 on switched antibody 
production, performed by Dr. Xinyan Li and Nick Hess, that are also presented in this chapter. 
Chapter Five draws together the findings on the function of TLR10 and offers insight on 
the potential role of TLR10 in B cell biology.  In addition, the chapter highlights future directions 
and questions, which remain to be answered, that would further advance knowledge of the 
signaling function of TLR10 and its potential as a therapeutic target for autoimmune diseases 
and hematologic malignancies. 
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CHAPTER 1 
GENERAL INTRODUCTION:  TOLL-LIKE RECEPTORS AND THE IMMUNE RESPONSE 
Activation of innate and adaptive humoral immunity 
The immune response to infection represents a highly coordinated interplay between 
sentinel cells bearing germline-encoded receptors and T and B lymphocytes, which use somatic 
recombination to establish antigen-specific recognition of invading microbes.  At the local site of 
infection, mast cells and macrophages, which reside in the tissue, recognize evolutionarily 
conserved components of microbes and upon recognition induce a signaling cascade that 
culminates in the production of pro-inflammatory cytokines and chemokines.  These molecules 
induce vascular permeability and the expression of integrin proteins on endothelial cells that 
serve to recruit blood mononuclear cells and granulocytes—predominantly monocytes and 
neutrophils—and guide them to the site of infection.  At the site of infection, these phagocytes 
efficiently engulf and destroy invading pathogens locally (Janeway, Travers, Walport 2001; 
Randolph, Jakubzick, Qu 2008). 
Concurrently, and early during the course of the infection, professional antigen 
presenting cells, namely dendritic cells (DC), engulf microbial invaders, process and present 
peptide antigens on major histocompatibility complex II (MHCII), and migrate through the 
lymphatic system to draining lymph nodes where T cells reside.  The recognition of MHC-
restricted peptide antigen by T cells in the lymph node results in the activation naïve T cells, 
which differentiate to effector T cells that either provide activating signals to B cells or home to 
sites of infection to aid in the destruction of invading pathogens. 
In addition, the lymphatic system carries free antigen to the lymph nodes, which 
become concentrated on the surface of follicular dendritic cells and are recognized by naïve B 
cells via the B cell receptor (BCR).  This activation serves as the first signal in B cell activation.  
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Upon stimulation by DCs that have traveled from the periphery, naïve T cells become T-helper 
cells which then localize to B cell-rich germinal centers in the lymph node where they interact 
with and help B cells to become activated by stimulating CD40 with CD40L found on the helper T 
cell surface.  This serves as the second signal for B cell activation.  The two signals required for B 
cell activation and differentiation into antibody-producing plasma and memory cells result in a 
robust yet highly specific humoral immune response, which occurs several days to a week after 
the initial infection.  
 
B cell receptor signaling and the humoral response 
As mentioned above, B cells classically require two distinct signals to achieve full 
activation.  The first signal is provided by the cross-linking of the B cell receptor (BCR) by free 
antigen that has traveled to lymph nodes via draining lymphatics, and the second signal comes 
from helper T cells, which have become activated via MHC-restricted recognition of peptide 
antigen on the surface of draining antigen-presenting cells through the T cell receptor (TCR).  
The requirement for both signals for full activation of B cells is most clearly evidenced in hyper-
IgM syndrome patients, where an X-linked defect in T cell CD40L results in deficient production 
of switched antibody isotypes, but increased serum titers of IgM (Callard et al. 1993). 
Over the past thirty years, much has become known with regards to specific signaling 
events that emanate from the BCR and the profound effects of numerous co-receptors that aid 
in B cell activation.  The B cell receptor consists of an antigen-binding membrane 
immunoglobulin in complex with Igα/β molecules that provide intracellular scaffolds that 
mediate signaling.  Binding of multivalent antigens—such as repetitive structures found on 
bacterial cell walls and viruses—by the BCR mediates clustering of the receptor on the cell 
surface, and such clustering events result in the activation of intracellular signaling molecules, 
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namely tyrosine kinases that propagate signals via phosphorylation of tyrosine residues.  Lyn, a 
Src-family kinase that closely associates with components of the BCR, is a proximal tyrosine 
kinase and serves as the first mediator of intracellular signaling by phosphorylating 
immunoreceptor tyrosine activation motifs (ITAM) on the intracellular Igα/β component of the 
BCR complex.  Phosphorylation of intracellular domains presents a scaffold that recruits 
additional signaling molecules, including the kinase Syk, phospholipase-Cγ2 (PLCγ2), 
phosphoinositol 3-kinase (PI3K), and Bruton’s tyrosine kinase (Btk), along with numerous other 
adaptor molecules.  The primary downstream cellular events are mediated through second 
messengers such as intracellular calcium release and induction of gene expression (Baba and 
Kurosaki 2016; Kurosaki, Shinohara, Baba 2010; Okkenhaug and Burger 2016). 
While the adaptive and innate arms of the immune response have traditionally been 
distinct areas of study, numerous mechanisms are known to serve as bridges between the two.  
In addition to the complement receptor complex (CR2/CD19) on the B cell surface, which allows 
BCR signaling to integrate signals from innate immune complement activation, the induction of 
pro-inflammatory cytokines and up-regulation of co-stimulatory molecules initiated by pattern 
recognition receptors on sentinel cells also play a key role in activating adaptive immunity via 
the direct programing of helper T cells.  More recently, however, B cell-intrinsic Toll-like 
receptor signaling has become fully appreciated in the context of B cell activation, blurring the 
line between the innate and adaptive arms of immune defense (Barr et al. 2009; Bernasconi, 
Onai, Lanzavecchia 2003; Fillatreau and Manz 2006; Nemazee et al. 2006; Pone et al. 2012). 
 
Toll-like receptor signaling 
Toll-like receptors (TLR) are classically a subfamily of pattern-recognition receptors 
(PRR) that serve an important role in innate immune defense and the initiation of inflammation.  
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Such pattern-recognition receptors are germline-encoded, recognize conserved components of 
microbes and endogenous danger signals that are initiated upon infection and stress, and result 
in the induction of pro-inflammatory signaling. 
While the Toll gene was first established as a key protein involved in the embryonic 
development of dorsoventral polarity, subsequent studies identifying a role for the Toll gene in 
immunity were first reported in Drosophila lacking components of the Toll signaling pathway.  
Toll-deficient flies were found to have a severely abrogated antimicrobial response and succumb 
to fungal challenge (Lemaitre et al. 1996).  The evolution of TLR genes across the animal 
kingdom has since been thoroughly studied (Leulier and Lemaitre 2008), and investigators have 
reported the expression of TLR genes from virtually all animal phyla, with the exception of 
flatworms.  The number of TLRs expressed in metazoans ranges from 1 in the starlet sea 
anemone to well over 200 in sea urchins.  However, non-vertebrate TLRs show little to no 
functional homology to mammalian TLRs. To date, investigation of TLRs in mammalian biology 
has been heavily reliant on mouse models.   
Shortly after the findings of Lemaitre et al., investigators discovered that the CH3/HeJ 
strain of mice, which were hyporesponsive to endotoxin, had a naturally occurring mutation in 
the TLR4 gene (Poltorak et al. 1998). Independently, others reported that mice lacking Myeloid 
differentiation antigen (MyD88), a key proximal signaling adaptor in the TLR and IL-1 pathway, 
exhibit a deficiency in response to endotoxin from gram-negative bacteria, as well as increased 
susceptibility to gram-positive Staphylococcus aureus infection (Kawai et al. 1999; Ku et al. 2007; 
Medzhitov et al. 1998).  The important role of TLR signaling in human immunity is evidenced in 
patients with an inherited deficiency in IRAK-4, another key adaptor molecule common to the 
TLR family (Ku et al. 2007; Muzio et al. 1997).  These individuals experience recurrent pyogenic 
infections, especially as young children, but notably, show no marked immune deficiencies as 
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adults.  A total of ten TLRs have been identified in humans, nine of which have been well-
characterized in heterologous systems and are known to induce pro-inflammatory signaling 
upon recognition of specific microbial agonists (Takeuchi et al. 2000; Underhill et al. 1999).  The 
tenth TLR is an orphan receptor with no known recognition or signaling capability and is the 
subject of our investigation. 
Structurally, TLRs are Type I transmembrane receptor proteins characterized by the 
presence of an extracellular ligand-recognition domain comprised of leucine-rich repeats (LRR) 
and an intracellular signaling domain.  The solenoid-shaped extracellular domains of TLRs are 
responsible for ligand recognition and form functional dimers that initiate signaling responses.  
TLR3, 4, 5, 7, 8, and 9 form homodimers and recognize viral double-stranded RNA, 
lipopolysaccharide, flagellin, viral nucleoside analogs, and unmethylated CpG motifs.  TLR2, 1, 
and 6 have the unique ability to form heterodimers and recognize lipidated components of the 
bacterial cell wall.  Upon recognition of such conserved microbial agonists, the intracellular 
Toll/Interleukin-1 Receptor homology domain (TIR domain) of TLRs are brought into close 
proximity and directly engage cytoplasmic adaptor molecules such as MyD88, TIR domain-
containing adaptor protein (TIRAP)/MyD88 adaptor-like (MAL), TIR domain-containing adapter 
inducing interferon-β (TRIF), and TRIF-related adaptor molecule (TRAM), each of which possess 
their own TIR domains that allow them to engage the TLRs through homotypic interactions 
(O'Neill and Bowie 2007).  All of the functional TLRs, except TLR3, employ MyD88 as their 
proximal signaling adaptor.  TLR2 and TLR4 signaling requires TIRAP/MAL in MyD88 
engagement.  MyD88 serves to recruit interleukin-1 receptor-associated kinase 4 (IRAK4) and 
IRAK1 to form a complex that links the TLRs to tumor necrosis factor receptor associated factor 
6 (TRAF6), ultimately leading to nuclear factor kappa B (NF-κB) activation (Brikos and O'Neill 
2008).  TLR3 utilizes the adaptor TRIF, and upon recognition of viral double-stranded RNA, 
6 
 
signals the production of Type I Interferons that are integral in antiviral response.  Additionally, 
TLR4, 7, 8, and 9 have also been shown to activate interferon regulatory factor (IRF) proteins 
that induce production of Type I Interferons.  These TLRs use MyD88 and the IRAK complex to 
activate IRF5 and IRF7 through TRAF6.  MyD88 can also interact with IRF1 directly to induce 
interferon production (Kawasaki and Kawai 2014). 
 
TLRs in innate immunity 
The functional role of TLRs in immune defense has been well established in a variety of 
model systems.  Mammalian TLRs are highly expressed on macrophages and DCs, and they 
recognize conserved components of microbial invaders.  A subset of TLRs are expressed on the 
cell surface and recognize components of the bacterial and fungal cell wall, while the other 
subset of TLRs are expressed within endosomes and recognize nucleic acid components found in 
microbes.  Recognition of microbial and endogenous danger signals results in the activation of a 
series of proinflammatory cytokines and chemokines via NF-κB.  These molecules include TNF-α, 
IL-6, IL-8, IL-1, and IL-12, which work in synchrony to initiate a potent immune response that 
locally promote vasodilation and vascular leakage, resulting in the recruitment of additional 
leukocytes to the periphery.  Systemically, the innate immune response also results in the 
production of acute phase proteins and increased white blood cell production.  These responses 
work in unison to fight infection. 
Additionally, TLR signaling in antigen presenting cells results in the upregulation of 
MHCII and co-stimulatory B7 molecule expression that are pivotal to the induction of adaptive 
immunity (Janeway, Medzhitov, Preston-Hurlburt 1997).  T cells that fail to receive these co-
stimulatory signals are known to undergo apoptosis or enter into an anergic state.  Indeed, 
emerging evidence suggests that the innate immune cell response utilizes synergy and crosstalk 
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between multiple TLR signals, and between TLRs and other PRRs, to produce an optimal 
response specific to the pattern of signals received (Randolph, Jakubzick, Qu 2008; Singh, Cox, 
Schwartz 2007).  Finally, TLR signaling produces numerous negative feedback mechanisms, 
including the production of IL-10 and TGF-β, that serve to modulate the immune response and 
initiate the healing process that marks the resolution of inflammation (Kawai and Akira 2010; 
Kondo, Kawai, Akira 2012; Takeda and Akira 2005). 
 
The emergent role of B cell-intrinsic TLRs 
While the integral role of TLR signaling in innate immune defense has been clearly 
established over the past 15 years, B cell-intrinsic TLR function has only recently come to light.  B 
cells are central players in humoral immunity that, when activated, become antibody-secreting 
plasma cells or survive as long-lasting memory cells.  As described previously, B cells are 
classically activated to clonally expand and produce antibody through activation of the B cell 
receptor (BCR), recognition of MHC-restricted antigen by helper T cells, and subsequent co-
stimulation of CD40 by CD40L found on the surface of helper T cells.  Alternatively, however, B 
cells can be activated independent of T cell help through multivalent BCR cross-linking by a 
repeating antigen such as a complex polysaccharide.  In either case, numerous studies have 
highlighted the importance of B cell intrinsic TLR signaling in the stimulation of a robust B cell 
response (Meyer-Bahlburg, Khim, Rawlings 2007; Nemazee et al. 2006; Pasare and Medzhitov 
2005).  
Using RT-PCR analysis, investigators have reported that human B cells express significant 
levels of TLR1, TLR6, TLR7, TLR9, and TLR10 (Bohnhorst et al. 2006; Booth et al. 2010; Dasari et 
al. 2005; Hornung et al. 2002; Mansson et al. 2006). Additionally, TLR activation alone enables 
extrafollicular B cells to undergo activation in response to conserved microbial agonists. 
8 
 
Published examples of this include proliferative B cell responses to unmethylated CpG DNA (a 
TLR9 agonist), upregulation of IgM production in murine B cells upon addition of 
lipopolysaccharide (LPS, a TLR4 agonist), and increased production of antibodies and cytokines 
in B cells in response to R848 (a synthetic antiviral product known to be recognized by TLR7 and 
TLR8) (Ganley-Leal, Liu, Wetzler 2006; He, Qiao, Cerutti 2004; Krieg et al. 1995; Lau et al. 2005; 
Lee et al. 1992; Vos et al. 2000). 
The requirement for B cell intrinsic TLR signaling is perhaps best highlighted in adoptive 
transfer experiments where MyD88 deficiency was restricted to B cells.  In these studies, 
investigators observed that antibody responses to protein antigens were dependent on TLR 
stimulation (Pasare and Medzhitov 2005).  Additional experiments using adoptive transfer of 
MyD88-deficient B cells into B cell deficient mice revealed that TLR responses are upregulated in 
the germinal center reaction, resulting in enhanced IgM production (Meyer-Bahlburg, Khim, 
Rawlings 2007).  Subsequent studies have confirmed the ability of B cell intrinsic signaling to 
induce germinal center formation and antibody production (Ganley-Leal, Liu, Wetzler 2006; 
Gerondakis, Grumont, Banerjee 2007).  Lastly, TLR agonists Pam3 and LPS have been shown to 
increase proliferation of human multiple myeloma cell lines, implicating TLR signaling in the 
progression of B cell leukemias (Bohnhorst et al. 2006).  Importantly, using RNA interference 
screening, Ngo and colleagues uncovered the importance of MyD88, IRAK1, and IRAK4 in the 
proliferative capacity of a particularly malignant subtype of diffuse large B cell lymphoma.  
Indeed, further RNA sequencing analysis revealed activating mutations in MyD88 in these cell 
lines (Ngo et al. 2011; Ngo et al. 2006).  Even more strikingly, a somatic variant resulting in an 
activating mutation in MyD88 that triggers IRAK-mediated NF-κB signaling was discovered to be 
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present in 91% of patients with Waldenstrom’s macroglobulinemia, an IgM-secreting 
lymphoplasmacytic lymphoma (Treon et al. 2012). 
Recognition of the importance of TLRs in B cell biology has also led to significant 
breakthroughs in our understanding of autoimmune pathologies where B cells play a central 
role.  An example of such a disease is systemic lupus erythematosus, an autoimmune disorder 
characterized by B cell hyperactivity and overproduction of autoantibodies.  It is thought that 
TLRs play a key role in stimulating autoreactive B cells to produce antibodies that bind self DNA-
protein complexes (Herlands et al. 2008; Horton, Pan, Farris 2010; Pisitkun et al. 2006; Richez et 
al. 2011).  These complexes then deposit in vascular tissue and induce inflammatory responses, 
resulting in subsequent vasculitis and tissue damage.  Leadbetter et al. made an important 
discovery in 2002 showing that B cells can be activated by chromatin-IgG complexes via dual 
engagement of BCR and TLR9 (Leadbetter et al. 2002).  This key finding implicated TLR signaling 
as a requirement for the propagation of anti-nuclear antibodies in the progression of SLE.  Later 
findings have also pointed to the involvement of TLR7 in the activation of autoreactive B cells 
(Lau et al. 2005).  Importantly, it was reported that the predisposition to autoimmune disease 
found in mice with the Y-linked autoimmune accelerator (Yaa) locus was due to a duplication in 
the TLR7 gene (Pisitkun et al. 2006).  The important role of TLR signaling in autoimmune blood 
disorders has also been shown in gene association studies, which have identified polymorphisms 
in several genes encoding TLR signaling components, including IRF5, IRAK1 and TNFAIP3, which 
predispose individuals to lupus. These findings together point to a strong therapeutic potential 
for TLRs in autoimmune disease and hematologic malignancies. 
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TLR 10 is an orphan TLR member expressed in B cells 
The focus of this dissertation is on TLR10, the only remaining orphan member of the 
human TLRs whose natural agonist recognition and signaling function is as yet unknown.  The 
TLR10 gene was first cloned by Chuang and Ulevitch in 2001, who reported strong mRNA 
expression in lymphoid tissues and B cell lines (Chuang and Ulevitch 2001).  To date, the 
differential expression of TLR10 mRNA between species and cell types has been investigated by 
numerous labs, revealing a unique expression profile that is largely restricted to B cells, 
implicating TLR10 as a modulator of B cell activity.  TLR10 is conserved in all mammals in which 
the TLR10 gene has been explored; however, importantly, it is a pseudogene in mice, where 
numerous retroviral insertions and sequence gaps have rendered the TLR10 gene nonfunctional.  
While other rodent species do have a TLR10 gene, the evolutionary rationale for the loss of 
TLR10 in mice remains an open question.  Nonetheless, in light of the heavy reliance on gene 
knock-out mouse models in the study of TLR function and the field of immunology in general, 
the loss of TLR10 in mice poses an important obstacle which has prevented a better 
understanding of its function. 
In humans, the TLR10 gene appears on chromosome 4, immediately adjacent to the 
genes encoding TLR1 and TLR6.  It is most closely related to TLR1, with close to 50% identity 
between their primary sequences.  However, phylogenetic analysis suggests an earlier 
divergence between a TLR1/6 precursor and TLR10, with a more recent divergence between 
TLR1 and 6.  The tandem arrangement of TLRs 1, 6, and 10 on chromosome 4 strongly suggests 
that the TLR 1, 6, 10 cluster originated evolutionarily as a result of gene duplication.  In the case 
of TLR6, it has been shown that this TLR expands the ligand recognition capability of the TLR2 
subfamily, but contributes no new signaling effects (Farhat et al. 2008; Takeuchi et al. 2001).  
However, an alignment of TLR1, 6, and 10 reveals important differences in the TIR signaling 
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domain of TLR10 from that of TLR1 and 6, including a number of changes within the BB loop and 
numerous amino acid insertions and substitutions, suggesting a divergent signaling function for 
TLR10.  Importantly, our lab recently reported that TLR10 may share recognition capabilities 
with TLR1, but fails to induce typical TLR signaling (Guan et al. 2010).  Here, Guan et al. reported 
that chimeric receptors of the TLR10 extracellular domain fused with the functional TLR1 
signaling domain were able to produce TLR signaling to NF-κB in cooperation with TLR2.  
However, the configuration of TLR1 extracellular and TLR10 signaling domain, either alone or in 
cooperation with TLR2, produced no output to any traditional TLR signaling pathways.  
Interestingly, however, our lab was able to detect a direct interaction between TLR10 and the 
proximal signaling adaptor MyD88 via co-immunoprecipitation experiments.  The crystal 
structure of the TLR10 intracellular signaling domain reveals a dimer in the asymmetric unit, 
with a dimer interface consisting of residues in the BB loop of the TLR10 TIR domain, posing the 
possibility that TLR10 acts as a functional homodimer (Nyman et al. 2008). 
As previously mentioned, an interesting feature of TLR10 is its unique pattern of 
expression, which has been reported in low levels in regulatory T cells (Treg), B cells, and 
plasmacytoid dendritic cells (pDC) (Bell et al. 2007; Bourke et al. 2003; Hasan et al. 2005).  The 
transcription factor FOXP3, critically important in the development and function of Treg cells, 
has been shown to form a cooperative complex with NF-AT in these cells to control production 
of TLR10 mRNA (Bell et al. 2007).  Mouse and human pDCs, which are precursors of mature 
dendritic cells, but share similar morphology with B cells, produce high levels of interferon-α/β, 
and this production is enhanced upon stimulation by viral and microbial stimuli recognized by 
TLRs present in these cells, which include TLR1, 6, 7, 9, and 10 (Kadowaki et al. 2001).  Finally, 
while the role of TLR signaling in B cells has recently been identified as an important third signal 
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in B cell activation, the precise role of TLR10 in the context of B cell activation has yet to be 
elucidated and thus is the primary focus of this thesis.  
 
Thesis Outline 
TLR10 is the only remaining orphan TLR in the human repertoire, with a unique 
expression pattern that is largely restricted to B cells.  Given the established role of TLR signaling 
in both the innate and adaptive arms of immune defense, establishing the function of TLR10 in 
the context of the immune response may not only shed light on why the gene has been 
propagated through evolutionary history, but also provide a novel target in the treatment of 
immune diseases. 
In Chapter Two, I present studies establishing TLR10’s capacity as a general suppressor 
of pro-inflammatory TLR signaling.  Given the lack of TLR10 expression in mice, our approach 
was to use ectopic expression of TLR10 in cell lines and transgenic mice.  Our studies revealed an 
inhibitory role for TLR10 in the context of immune responses to numerous TLR signals.  Using 
stable cell line and transient transfection models, we established the role of TLR10 as a negative 
regulator of both MyD88 and TRIF dependent signaling.  We also reported that ligation of TLR10 
in whole blood using a monoclonal antibody created by Guan et al. resulted in strongly 
attenuated responses to TLR agonists (Guan et al. 2010). 
In Chapter Three, I report studies investigating the expression of TLR10 within the B cell 
lineage.  While numerous studies have shown the presence of TLR10 mRNA in cell lines and 
primary cells, the lack of a reliable commercially available antibody to TLR10 prevented careful 
investigation of TLR10’s surface expression.  However, with Dr. Yue Guan’s careful work in 
establishing a monoclonal antibody specific for TLR10, we were able to use this reagent to 
investigate the regulation of TLR10 expression in blood leukocytes and tonsillar tissue.  Our 
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investigations led to the validation that significant levels of TLR10 are found on CD19+ B cells 
and that this surface expression is attenuated along progressive stages of B cell activation within 
lymphoid tissue. 
In Chapter Four, I present studies investigating the precise role of endogenous TLR10 in 
the context of B cell activation.  Using an activating anti-TLR10 monoclonal antibody previously 
developed in our lab, we report that stimulation of TLR10 in human peripheral blood B cells 
results in strongly attenuated B cell proliferation, cytokine production, and induction of B cell 
activation genes.  Additionally, we report a subtle effect on B cell signaling events via 
phosphorylation of B cell signaling molecules.  These findings are further corroborated with 
concurrent transgenic mouse studies that reveal profound suppressive effects of TLR10 on 
switched antibody production performed by Dr. Xinyan Li and Nick Hess. 
In Chapter Five, I draw together our findings on the function of TLR10 and offer 
concluding remarks on the potential role of TLR10 in B cell biology.  In addition, I offer some 
thoughts on future directions that would further advance our knowledge on TLR10’s signaling 
function and its potential as a therapeutic target for autoimmune and hematologic 
malignancies. 
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CHAPTER 2 
TOLL-LIKE RECEPTOR 10 IS A NEGATIVE REGULATOR OF BOTH MYD88-DEPENDENT AND            
–INDEPENDENT TLR SIGNALING1 
Abbreviations 
TIR, Toll/Interleukin Receptor; MyD88, Myeloid Differentiation Factor 88; TRIF, TIR-
domain-containing adaptor-inducing interferon-β; PAM3CSK4, N-Palmitoyl-S-[2,3-
bis(palmitoyloxy)-(2RS)- propyl]-[R]-cysteinyl-[S]-seryl-([S]-lysine)4; pI:C, 
polyinosinic:polycytidylic acid. 
 
Abstract 
Toll-like receptors are central components of the innate immune system which, upon 
recognition of bacterial, fungal or viral components, activate intracellular signals that lead to 
protective inflammatory responses.  Among the ten-member human TLR family, TLR10 is the 
only remaining orphan receptor without a known ligand or signaling function.  Murine TLR10 is a 
disrupted pseudogene, which precludes investigation using classic gene knock-out approaches. 
We report here that TLR10 suppressed the production of an array of cytokines in stably 
transfected human myelomonocytic U937 cells in response to other TLR agonists.  This broad 
TLR suppressive activity affects both MyD88 and TRIF-mediated signaling pathways upstream of 
IκB and MAPK activation.  Compared to non-transgenic littermate controls, monocytes of TLR10 
transgenic mice exhibited blunted IL-6 production following ex vivo blood stimulation with other 
TLR agonists.  After intraperitoneal injection of LPS, lower levels of TNF-α, IL-6 and type-1 IFN 
                                                          
1 This chapter appeared in its entirety in the Journal of Immunology and is referred to later in this 
dissertation as “Jiang et al. 2016”.  Jiang, S., Li, X., Hess, N., Guan, Y., Tapping, R.I. 2016. TLR10 Is a 
Negative Regulator of Both MyD88-Dependent and –Independent TLR Signaling.  The Journal of 
Immunology. Epub 2016 Mar 28. 
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was measured in the serum of TLR10 transgenic mice, compared to non-transgenic mice, but did 
not affect mouse survival in an LPS-induced septic shock model.  Finally, treatment of human 
mononuclear cells with a monoclonal anti-TLR10 antibody suppressed pro-inflammatory 
cytokine release mediated by other TLR agonists.  These results demonstrate that TLR10 
functions as a broad negative regulator of TLR signaling and suggests TLR10 may have a role in 
controlling immune responses in vivo.  
 
Introduction 
Toll-like receptors are type-1 transmembrane receptors that are part of a broad class of 
innate immune receptors known as pattern-recognition receptors.  TLRs serve as the first line of 
defense against infectious pathogens by initiating protective inflammatory responses following 
the direct sensing of bacterial, fungal or viral components.  Recognition of a cognate microbial 
ligand by the extracellular leucine-rich repeat domain of each TLR leads to receptor dimerization 
(Kawai and Akira 2010).  This event dimerizes two C-terminal TIR-domains which provide a 
scaffold for the recruitment of other cytosolic TIR-domain containing adaptor molecules that 
propagate intracellular signaling (Gay et al. 2014; Kawasaki and Kawai 2014).  
Humans possess 10 TLR family members, numbered 1 through 10, subsets of which are 
expressed in leukocytes and various tissue cells (Chuang and Ulevitch 2001; Hornung et al. 
2002).  TLRs 1, 2, 4 and 6 traffic to the plasma membrane, sense microbial and fungal cell wall 
components and stimulate the production of classic proinflammatory molecules.  TLRs 3, 7, 8 
and 9 are located in endosomal compartments, sense viral and bacterial nucleic acids and are 
best known for their ability to stimulate the production of Type-1 IFNs (Gay et al. 2014).  Almost 
all TLRs utilize the TIR-domain containing adaptor MyD88 which upon recruitment to dimerized 
TLRs at the plasma membrane induce the activation of NF-κB and other transcription factors 
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that promote expression of classic pro-inflammatory cytokines (Lin, Lo, Wu 2010).  TRIF is 
utilized by both TLR3 and endosomal TLR4 and, in a MyD88 independent manner, drives the 
expression of Type-1 IFN production through activation of the transcription factor interferon 
response factor 3 (Gay et al. 2014).  
To date, we have a fairly clear understanding of the ligand recognition, signaling and 
biological functions of human TLRs 1 through 9.  In contrast, TLR10 is the only remaining orphan 
human TLR without a confirmed ligand, signaling pathway or biological function.  The TLR10 
gene was first cloned in 2001 and various analyses has revealed strong expression in the 
lymphoid tissues including the spleen, lymph node, thymus and tonsils (Chuang and Ulevitch 
2001; Hornung et al. 2002).  TLR10 is expressed among a number of leukocyte subtypes and 
perhaps most prominently by B cells.  A major obstacle toward defining a function for TLR10 is 
that several retroviral insertion elements have rendered TLR10 a pseudogene in mice thus 
precluding a classic knockout mouse model (Hasan et al. 2005).  Although TLR10 is disrupted in 
mice, every other mammal sequenced to date contains an undisrupted TLR10 gene including 
numerous primate species, domestic animals and a variety of rodents (Mikami et al. 2012; 
Roach et al. 2005). 
TLR10 is most homologous to TLR1 and TLR6 which both cooperate with TLR2 to 
mediate inflammatory responses to a variety of microbial lipids including bacterial lipoproteins 
(Mikami et al. 2012; Roach et al. 2005).  Previously, we have shown that TLR10, either alone or 
in cooperation with TLR2, fails to induce typical TLR-associated signaling events including 
transcriptional activation of NF-κB, IL-8 and IFN-β promoters (Guan et al. 2010).  Sequence 
analysis has revealed that the TIR domain of TLR10 is less conserved and has a calculated rate of 
evolutionary change that is higher than that of any other TLR (Mikami et al. 2012).  This suggests 
that TLR10 may have a unique function among the TLR family. 
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To assess the function of human TLR10 we have generated stably transfected monocytic 
cells lines, a transgenic mouse model, as well as biologically active monoclonal antibodies to the 
receptor.  Collectively, our findings support the idea that TLR10 is an anti-inflammatory 
receptor. Importantly, we also show that the TLR10-mediated suppression broadly effects both 
MyD88 and TRIF-dependent signaling pathways making TLR10 a potential global suppressor of 
TLR signaling. 
 
Materials and Methods 
Reagents 
Antibodies specific for phospho p38 (clone D3F9), phospho-JNK (clone 81E11), phospho-
ERK (clone D13.14.4E), IκBα (clone 44D4) and β-actin (clone 13E5) were from Cell Signaling 
Technologies (Beverly, MA). Anti-FLAG antibody (clone M2) are from Sigma-Aldrich (St. Louis, 
MO).  FITC conjugated CD11b (clone 3A33) were from Abcam (Cambridge, MA).  Directly 
conjugated antibodies to Ly6G (clone 1A8) and IL-6 (clone MP5-20F3) were from BioLegend (San 
Diego, CA).  The synthetic triacylated lipopeptide Pam3CSK4 was purchased from Alexis 
Biochemicals (San Diego, CA), LPS from E. coli strain K235 and pI:C were from Sigma-Aldrich. 
Monoclonal antibodies against the extracellular domain of recombinant human TLR10 were 
produced in-house.  One clone, 3C10C5, is commercially available.  The antibody clone used in 
this study is 5C2C5. The isotype control used was MOPC-21, a murine IgG1 with no known 
specificity. 
 
Plasmid Constructs 
Expression constructs for TLR10, TLR1, TLR1-10, TLR10-1, CD4-TLR10, CD4-TLR1, MyD88, 
TRIF, IL-8 promoter driven luciferase, IFN-β promoter driven luciferase, and Renilla-luciferase 
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transfection control are previously described (Guan et al. 2010).  The pMX-IRES-Puro expression 
vector, used for the production of retrovirus, was purchased from Cell Biolabs (San Diego, CA).  
This vector was then modified to include a preprotrypsin leader sequence and a FLAG linker 
region into which the coding region of TLR10 was sub-cloned to generate pMX-FLAG-TLR10.  The 
CMV-FLAG-TLR10 plasmid, used in the generation of TLR10 transgenic mice, was constructed by 
inserting the TLR10 coding sequence lacking the endogenous signal peptide into pFLAG-CMV 
vector (Sigma-Aldrich).  
 
Development of Stable Cell Lines 
The NIH3T3 amphoteric packaging line was plated in 10cm dishes and transfected with 
either pMX-FLAG-TLR10 or the empty pMX-FLAG vector using FuGene 6 according to 
manufacturer’s instructions (Roche, Indianapolis, IN).  Forty-eight hours after transfection, viral 
supernatants were cleared of cell debris and applied to parental U937 cells during log phase 
growth.  Twenty-four hours after viral transduction, virus was removed and stably transduced 
cells were selected in media containing 2 µg/ml Puromycin (Sigma-Aldrich).  Batch derived cells 
were expanded and surface expression of the FLAG epitope was verified. 
 
Cell Culture and TLR Stimulation 
Human cell lines were cultured in RPMI medium supplemented with 10% FBS, 2mM L-
Glutamine, 100 IU/ml Penicillin, and 100 µg/ml Streptomycin.  Stably transduced U937 cells 
were kept under selection in the presence of 2 µg/ml Puromycin (Sigma-Aldrich).  To investigate 
cytokine production, cells were plated at 5x104 cells per well in 96-well plates and differentiated 
with PMA at 100 ng/ml for 48 hours.  Cells were then washed and allowed to rest in fresh media 
for 24 hours.  Media was replaced before cells were stimulated with either 50ng/ml PAM3CSK4, 
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50 µg/ml pI:C, or 50 ng/ml LPS. Cells were stimulated overnight with the indicated agonist and 
cell-free supernatants were collected for cytokine analysis. 
 
Transient Transfection Assays 
HEK293T cells were transfected in 12-well plates using FuGene 6 with vectors encoding 
either MyD88 or TRIF constructs (20 ng/ml), TLR vectors (100 ng/ml), either IL-8 or IFN-β 
luciferase reporter (150 ng/ml) and Renilla luciferase as a transfection control (50 ng/ml).  
Luciferase readings were obtained using the Dual-Luciferase Assay Kit (Promega, Madison, WI) 
according to the manufacturer’s instructions. 
 
Real-time PCR Analysis 
U937 cell lines were plated at 2x106 cells/mL and differentiated for 48 hours in 100 
ng/ml PMA.  Media was changed and cells were allowed to rest for 24 hours before stimulation 
with 100 ng/ml PAM3CSK4 for 4 hours.  After stimulation, cells were harvested and RNA was 
isolated using the RNeasy kit (Qiagen, Hilden, Germany).  RNA quality was assessed by 
spectrophotometry and agarose gel electrophoresis.  Specific mRNA transcripts were quantified 
using the SABiosciences TLR pathway qPCR Array (Qiagen), according to manufacturer’s 
instructions.  The array includes analysis of 84 genes involved in TLR signaling plus five 
housekeeping genes for normalization as well as controls for genomic DNA contamination, RNA 
quality, and general PCR performance.  
 
Analysis of MAPK Signaling and NFκB Activation 
Vector control and TLR10-expressing U937 cells were stimulated with either 50 ng/ml 
PAM3CSK4, 50 µg/ml pI:C or 50 ng/ml LPS for the indicated time periods.  Cell lysates were 
 25 
 
prepared from 1x107 cells in RIPA lysis buffer (150mM NaCl, 50mM Tris-HCl PH8.0, 1% NP-40, 
1mM EDTA) supplemented with the Halt protease and phosphatase inhibitor cocktail (Thermo 
Scientific, Rockford, IL).  Equal amounts of protein lysate were loaded on SDS-PAGE gels, 
transferred to PVDF membranes and blotted using specific antibodies (Cell Signaling 
Technologies, Beverly, MA). 
 
Development of TLR10 Transgenic Mice 
CMV-FLAG-TLR10 plasmid (Guan et al. 2010) was digested with Spe1 and Stu1 and 2μg 
of the purified linearized CMV-FLAG-TLR10 double stranded DNA was injected into C57BL/6 
(Harlan Laboratories) fertilized oocytes.  Early embryos were then transferred into Swiss 
Webster pseudo pregnant fosters to generate transgenic founders.  Pups were weaned and 
genotyped using a primer set specific to the 5’ end of the transgene: Forward 5’-ACA AAG ACG 
ATG ACG ACA AGC-3’ and Reverse 5’-AAT AGA ACC GAT GTC TTA GC-3’.  A second primer set 
was specific to the 3’ end of the transgene: Forward 5’-ACT TTG TCC AGA ATG AGT GG-3’ and 
Reverse 5’-TAT TAG GAC AAG GCT GGT GG-3’.  All transgenic mice were generated by the 
Transgenic Mouse Core Facility at University of Illinois Urbana-Champaign under an approved 
IACUC protocol. 
 
Southern Blot Analysis 
Mouse tail genomic DNA was isolated through proteinase K treatment and 
phenol:chloroform:isoamylalcohol (25:24:1) purification.  A total of 5 μg of genomic DNA was 
digested with Sac1 and separated on a 1% agarose gel. DNA was blotted onto Immobilon-Ny+ 
membrane (Millipore Inc.), washed with 6 x SSC buffer and then cross-linked using a UV 
Stratalinker (Agilent technologies).  Hybridization was carried out at 65C with a biotin-labeled 
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3’-transgene fragment containing the hGH polyA sequence of the CMV-FLAG-TLR10 vector as 
described by the manufacturer (South2North, Thermo Scientific).  Transgene copy number was 
estimated from copy number standards containing varying amounts of unlabeled probe DNA. 
 
Tissue RNA Extraction and RT-PCR 
Approximately 100 mg of mouse tissue was homogenized in 1 ml Trizol (Ambion Inc.) 
reagent using a Dounce homogenizer (Wilmad lab glass). RNA was then purified with 
PureLinkTM RNA purification kit (Ambion Inc.) and used to generate 1st strand cDNA with 
SuperScript III reverse transcriptase (Invitrogen Inc.).  PCR was carried out using the forward 
primer 5’-ACA AAG ACG ATG ACG ACA AGC-3’ and the reverse primer 5’-AAT AGA ACC GAT GTC 
TTA GC-3’.  
 
Western Blotting of TLR10 
Mouse tissue was ground with a Dounce homogenizer in 1 ml RIPA lysis buffer 
containing protease and phosphatase inhibitors.  Cell homogenate was then incubated on ice for 
2 hours followed by centrifugation at top speed for 15 minutes at 4C.  Total protein was 
separated on a 7% SDS-PAGE gel, blotted onto PVDF membrane (GE Healthcare) and probed 
with HRP conjugated anti-FLAG antibody (clone M2).   
 
Mouse Whole Blood Stimulation and Intracellular IL-6 Staining 
Mouse whole blood was collected from the lateral tail vein of age and gender matched 
non-transgenic and transgenic mice. 50 μL of whole blood was mixed with an equal volume of 
RPMI medium containing either 500 ng/ml PAM3CSK4, 100 µg/ml pI:C or 200 ng/ml LPS and 
incubated at 37C with gentle agitation overnight.  Centrifuged supernatants were assessed for 
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cytokines by standard ELISA. For intracellular IL-6 staining, 100 µl mouse whole blood was 
stimulated with 500 ng/ml LPS in the presence of Brefeldin A for 6 hours.  Red blood cells were 
lysed with ACK buffer and peripheral blood leukocytes were stained with anti-mouse CD11b and 
Ly6G antibodies.  Permeabilized cells were stained with directly conjugated anti-mouse IL-6 
antibody or isotype control antibody. 
 
Intraperitoneal Injection and Shock Assay 
Age and gender matched non-transgenic and transgenic mice (8-10 week old) were 
injected intraperitoneally with a high dose of LPS, 0111:B4 (20-25mg/kg).  Tail blood was 
collected at 1 and 4 hours post injection and serum was prepared and assayed for cytokines as 
above. In the shock assay, injected mice were monitored for survival for up to 7 days. 
 
Cytokine Assays 
Human IL-6 and IL-8 as well as mouse IL-6 and TNFα were analyzed by paired-antibody 
ELISA according to manufacturer’s instructions (Invitrogen, Grand Island, NY).  Type-I IFN was 
detected using an ISRE-L929 reporter cell line bioassay (a kind gift from Dr. Bruce Beutler, UT 
Southwestern).  Briefly, ISRE-L929 cells were plated at 2x104 cells per well in a 96-well format.  
Cell culture media was replaced 24 hours later with cell-free supernatant from either stimulated 
U937 cells or mouse serum. ISRE-L929 cells were incubated for another 6 hours and luciferase 
activity was detected in cell lysates using a luciferase reporter assay system (Promega). 
 
Human Mononuclear Cell Stimulation 
Primary human mononuclear cells were obtained from venous blood of consenting 
healthy adult volunteers under an approved IRB protocol.  Blood was mixed 1:1 in Leukocyte 
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Isolation Buffer (1X PBS, 2 mM EDTA, 2% FBS) before centrifuging over a Ficoll gradient 
(1.077g/L) at 1100xg for 15 min with no brake.  The resulting buffy coat was washed twice in cell 
culture media before plating 100 μL of ~2-5x104 cells in a 96 well plate.  Cells were allowed to 
pre-incubate in the presence of either an isotype control (clone MOPC-21) or anti-TLR10 
antibody (clone 5C2C5) before stimulation with either LPS (10 ng/mL), pI:C (5 μg/mL) or IFNβ 
(100 ng/mL).  After 24hrs, cell-free supernatants were collected and assayed by ELISA.  
 
Statistical Analysis 
All data were analyzed with two-tailed Student’s t test unless otherwise indicated. 
 
Results 
TLR10 is a Suppressor of TLR2/1-Induced Responses 
To examine the biologic function of TLR10, we stably expressed the receptor in U937 
cells, a human myelomonocytic line which we found lacks detectable endogenous TLR10 
expression (Fig. 2.1A).  Using MMLV retrovirus, a N-terminally tagged FLAG-TLR10 construct was 
stably transduced into U937 cells and TLR10 expression was confirmed by both RT-PCR and flow 
cytometry using an anti-FLAG antibody (Fig. 2.1A and 2.1B).  The stably transduced cell line 
exhibited no differences in cell growth or viability compared to either the parental or empty 
vector (MMLV) control lines (unpublished observation).  To explore potential signaling outputs 
of TLR10, we compared the CMV and TLR10 cell lines for the expression of 84 genes known to 
be targets of TLR signaling following stimulation with the TLR2/1 lipopeptide agonist PAM3CSK4. 
Compared to CMV-U937 cells, the RNA message for 11 genes had lower PAM3CSK4 induction 
levels in TLR10-U937 cells.  These genes included those encoding the pro-inflammatory 
cytokines TNFα, IL-1α, IL-6 and IFN-β (Table 2.1).  Supernatants from cells stimulated with 
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varying concentrations of PAM3CSK4 confirmed that TLR10-U937 cells secreted significantly 
lower levels of both IL-6 and TNFα (Fig. 2.2).  These data suggest that TLR10 mediates an anti-
inflammatory function in U937 cells stimulated with TLR2/1 lipopeptide agonist. 
 
TLR10 Inhibits TLR-Induced Inflammatory Responses 
To examine the specificity of TLR10 suppression, we stimulated the U937 cell lines with 
TLR agonists in addition to those for TLR2/1 (PAM3CSK4), including TLR2/6 (MALP-2), TLR3 (pI:C) 
and TLR4 (LPS).  Compared to CMV-U937 cells, TLR10-U937 cells secreted significantly less IL-6 in 
response to all the TLR agonists tested (Fig. 2.1C).  The secretion of type-1 IFNs following 
stimulation with the TLR3 agonist pI:C (Fig. 2.1D) was also markedly decreased in TLR10-U937 
cells.  The cell lines had indiscernible differences in IL-6 production in response to IFN-β, as well 
as indiscernible differences in type-1 IFN production in response to TNF-α.  Taken together these 
results support the idea that TLR10 broadly inhibits production of both IL-6 and IFN-β induced by 
a variety of TLRs, but not the production of these cytokines induced through other signaling 
pathways. 
 
TLR10 Suppresses IκBα Degradation and the Phosphorylation of MAPKs  
To gain insight into the mechanism of TLR10-mediated suppression we analyzed the 
effect of TLR10 on various canonical TLR signaling pathways including the activation of NF-κB 
and various MAP kinases.  As shown in Fig. 2.3, PAM3CSK4, pI:C and LPS each triggered IκBα 
degradation within 30 minutes of TLR stimulation in vector control cells.  However, degradation 
of IκBα was consistently inhibited in TLR10-expressing cells, suggesting that TLR10 suppresses 
NF-κB signaling upstream of IκBα degradation. TLR10-U937 cells also exhibited reduced ERK, 
JNK, and p38 phosphorylation levels compared to vector control cells following stimulation with 
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TLR agonists PAM3CSK4, pI:C or LPS.  Taken together, these results indicate that TLR10 acts as a 
broad suppressor of TLR-induced pro-inflammatory signaling including NF-κB and MAP kinase 
signaling pathways. 
 
TLR10 Suppresses MyD88 and TRIF Signaling   
The ability of TLR10 to broadly suppress responses from a variety of TLRs suggests that 
this receptor inhibits MyD88-dependent signaling.  To assess this we examined the effect of 
TLR10 on HEK293T cells expressing MyD88.  As expected, the overexpression of MyD88 in 
HEK293T cells resulted in strong constitutive induction of an IL-8 promoter-driven luciferase 
reporter (Fig. 2.4A).  Consistent with its suppressive role, co-expression of TLR10 resulted in an 
8-fold reduction of MyD88-induced IL-8 luciferase activity. In contrast, co-expression of TLR1, 
the closest homologue of TLR10, had no measureable effect. 
The inhibitory effect on TLR3-induced IFN-β production strongly suggests that TLR10 
also suppresses MyD88-independent signaling mediated by the adaptor TRIF.  To assess this we 
examined the effect of TLR10 on HEK293T cells expressing TRIF, which induces constitutive 
activation of IRF3 thereby driving Type 1 IFN production.  The overexpression of TLR10 resulted 
in a marked reduction of Type 1 IFN production, as measured by bioassay, while co-expression 
of TLR1 had no measureable effect (Fig. 2.4B).  Importantly, TLR10 suppression of both MyD88 
and TRIF-mediated pathways is dose-dependent (Fig. 2.5).  The data together suggest that TLR10 
acts as a negative regulator of pro-inflammatory TLR signaling, targeting both MyD88 and TRIF-
dependent TLR signaling. 
To assess the roles of the extracellular and TIR domains of TLR10 in suppression we 
generated chimeric receptors between TLR1 and TLR10.  Interestingly, neither a construct 
containing the extracellular domain of TLR1 and the intracellular domain of TLR10 (TLR1-10), nor 
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the reverse chimeric receptor (TLR10-1), were able to suppress either MyD88-dependent or 
TRIF-dependent activation, demonstrating that both domains of TLR10 are required for its 
suppressive function (Fig. 2.4, A and B).  To assess the role of receptor dimerization, we replaced 
the extracellular domain of TLR10 with that of CD4; an approach that has been shown to cause 
constitutive TIR domain-mediated signaling since CD4 naturally forms dimers.  Similar to full 
length TLR10, CD4-TLR10 inhibited both MyD88 and TRIF-dependent signaling. In contrast, CD4-
TLR1 had no effect on either MyD88 or TRIF signaling (Fig. 2.4, C and D).  Importantly, cellular 
expression of all the chimeric receptors was confirmed by flow cytometry (Fig. 2.6).  Taken 
together, these data suggest that TLR10 functions as a homodimer to suppress both MyD88 and 
TRIF-dependent TLR signaling. 
 
Development of TLR10 Transgenic Mice (Experiments performed by Dr. Xinyan Li) 
To explore the potential function of TLR10 in vivo, we developed a transgenic mouse 
line in which N-terminally FLAG-tagged human TLR10 is constitutively expressed behind a strong 
viral promoter. Thirty-two pups were derived from oocyte injection of the vector and then 
screened for the transgene with 14 PCR positive founders further analyzed by southern blot (Fig. 
2.7A).  A founder with an intermediate copy number of the transgene and broad tissue 
expression was selected from among the 14 candidates for further analysis (Fig. 2.7B).  TLR10 
expression levels were highest in the spleen with confirmed expression in blood leukocytes (Fig. 
2.7C). 
Founder mice showed no overt developmental abnormalities and reproduced at 
expected mendelian ratios.  However, two founders that exhibited the highest level of TLR10 
expression across a variety of tissues developed lethal urethral tract infections in the first two 
months of life. Necroscopy revealed a high concentration of Gram-positive bacteria including 
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Staphylococcus aureus as well as species of Enterococcus in the urine (unpublished observation). 
These observations suggest that high levels of TLR10 expression in mice may suppress the 
immune system allowing for the opportunistic overgrowth of commensal bacteria. 
 
TLR10 Transgenic Mice Exhibit Reduced TLR-Induced Responses (Experiments performed by 
Dr. Xinyan Li) 
To determine the effect of TLR10 expression on murine blood leukocytes we examined 
IL-6 production following ex vivo stimulation of whole blood with different TLR agonists. 
Production of IL-6 in whole blood of TLR10 transgenic mice was significantly lower than that of 
non-transgenic control mice in response to PAM3CSK4, pI:C and LPS (Fig. 2.8A).  The reduced 
cytokine production is not due to any significant differences in the numbers of peripheral blood 
monocytes or neutrophils between wild type and TLR10 transgenic mice (Fig. 2.9).  To identify 
the cell type(s) that are targeted by TLR10-mediated suppression, we stimulated mouse 
peripheral blood ex vivo with LPS and measured intracellular IL-6 by flow cytometry.  Monocytes 
(CD11b+, Ly6G-), but not neutrophils (CD11b+, Ly6G+), were shown to have suppressed IL-6 
production in response to LPS stimulation compared to equivalent cells from non-transgenic 
control mice (Fig. 2.8, B and C).  These data confirm our previous findings in human 
myelomonocytic cell lines and suggest that even in a murine background human TLR10 
maintains its function as an inhibitor of pro-inflammatory cytokine production. 
 
TLR10 Suppresses in vivo Response to LPS (Experiments performed by Dr. Xinyan Li) 
To assess the role of TLR10 in vivo, we measured blood cytokine levels in mice following 
intraperitoneal injection with a sub-lethal dose of LPS.  The induction of IL-6, TNF-α and type-1 
IFNs were all reduced in the TLR10 transgenic mice compared to the non-transgenic littermate 
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control mice (Fig. 2.10A).  To determine if TLR10 can protect mice from LPS-induced septic 
shock, we monitored survival following intraperitoneal injection of mice with a high, almost 
uniformly fatal, dose of LPS.  However, no significant difference in either mortality or time-to-
death was observed between TLR10 transgenic and non-transgenic mice (Fig. 2.10B).  These 
data show that TLR10 is able to suppress a broad array of TLR responses in both MyD88 and 
TRIF-dependent manners, but is not capable of protecting mice from LPS-induced septic shock in 
vivo.  
 
Endogenous TLR10 Suppresses Human Mononuclear Cell Activation (Experiments performed 
by Nick Hess) 
To assess the effect of TLR10 engagement on pro-inflammatory responses, we 
incubated human mononuclear cells isolated from the peripheral blood of healthy donors with 
either an anti-TLR10 antibody or a non-specific isotype matched control antibody.  These cells 
were then stimulated overnight with either the TLR4 agonist LPS or the TLR3 agonist pI:C. 
Compared to isotype control antibody, anti-TLR10 antibody suppressed the secretion of both IL-
6 and TNFα from the mononuclear cells of two independent donors (Fig. 2.11).  The suppression 
detected was dependent on the stimulus, as no difference in cytokine release by cells treated 
with the two different antibodies was observed following stimulation with IFN-β.  These data 
show that antibody engagement of endogenous human TLR10 in primary cells suppresses 
inflammatory responses mediated by either MyD88 or TRIF-dependent TLRs. 
 
Discussion 
Previously we have shown that the TLR10, either alone or with TLR2, fails to activate 
pro-inflammatory responses typically associated with this family of receptors (Guan et al. 2010). 
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In this paper, results stemming from a variety of experimental approaches support the idea that 
TLR10 functions as a broad suppressor of other TLRs, with inhibitory activity toward both MyD88 
and TRIF-dependent signaling.  We believe that, as a suppressor, TLR10 functions as a 
homodimer as evidenced by the fact that replacement of the extracellular domain of TLR10 with 
CD4, but not the extracellular domain of TLR1, results in a receptor that retains full suppressive 
function.  Consistent with this notion is the observation that the crystal structure of the TLR10 
TIR domain was solved as a symmetric homodimer (Nyman et al. 2008).  Additionally, using gel 
filtration chromatography, we have found that the TLR10 extracellular domain purifies as a 
homodimer (data not shown).  Together, these observations suggest that the extracellular 
domain and TIR domains of TLR10 contribute to homodimerization and that this event can be 
driven by either overexpression, in cell lines or mice, or through engagement of the endogenous 
receptor with a divalent monoclonal antibody. 
Among members of the TLR family, TLR10 is most homologous to TLRs 1 and 6 with 
highest homology observed within the signaling TIR domain (Roach et al. 2005).  In the crystal 
structure of the TLR10 TIR domain a portion of the BB loop forms part of the dimer interface but 
much of the loop is exposed and available to interact with TIR domain adaptor molecules such 
as MyD88 and TRIF (Nyman et al. 2008).  In this context, there are notable differences in key 
residues of the BB loop that mediate intracellular signaling which include a two amino acid 
insertion just before the BB loop as well as amino acid changes within residues of the BB loop 
itself.  Whether these difference are responsible for the suppressive activity of TLR10 remains to 
be investigated. 
In support of our studies, another report published last year revealed TLR10 as an anti-
inflammatory receptor that suppresses TLR2-mediated inflammatory responses in both human 
mononuclear cells and in a transgenic mouse model (Oosting et al. 2014).  In that study TLR10 
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was shown to suppress the release of a number of pro-inflammatory cytokines in response to 
the TLR2 agonists PAM3CSK4 as well as whole Borrelia burgdorferi.  In support of this, genetic 
polymorphisms in TLR10 have been shown to associate with variability of responses to bacterial 
lipopeptide (Mikacenic et al. 2013).  A number of possible mechanisms for suppression are 
proposed including possible competition for ligand and/or co-receptors as well as the induction 
of anti-inflammatory cytokine expression.  This study extends the suppressive function of TLR10 
to that of other TLR family members as well as to both MyD88 and TRIF-dependent signaling 
pathways.  Our analysis of signaling pathways indicate that TLR10 acts proximally in the signaling 
cascade through as yet undefined mechanism. 
Two other studies have proposed an opposite, pro-inflammatory, function for TLR10. 
One study showed that siRNA-mediated knock down of endogenous TLR10 in HT-29 colonic 
epithelial cells blunted inflammatory responses to Listeria monocytogenes (Regan et al. 2013). 
Another study, showed that knock down of TLR10 in the THP-1 myelomonocytic cell line 
inhibited cellular responses to the H1N1 and H5N1 flu virus strains (Lee et al. 2014). 
Interestingly, both studies revealed fairly broad effects on pro-inflammatory cytokine and type-1 
IFN production that were dependent on infection of cells with live pathogens, but not with heat-
killed pathogens.  Since both these organisms replicate in the cytoplasm, this suggests that 
intracellular forms of TLR10 may have a pro-inflammatory function following recognition of a 
PAMP associated with virulence (Mourao-Sa, Roy, Blander 2013).  In the study of flu virus, 
transfection studies suggested that TLR10 responds to viral ribonuclear protein complexes (Lee 
et al. 2014).  Although these findings contrast our own and others (Oosting et al. 2014), it is 
noteworthy that we have engaged endogenous TLR10 at the cell surface where it may possess 
an opposing signaling function. 
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The finding that TLR10 is a negative regulator among members of the TLR family is 
perhaps not surprising (Kondo, Kawai, Akira 2012).  Even within the closely related IL-1 receptor 
family, whose members have TIR domains and utilize MyD88 to propagate signaling, are two 
inhibitory receptors known as ST2 (Brint et al. 2004) and SIGIRR (Wald et al. 2003).  The 
transmembrane receptor ST2 has been shown to suppress NF-κB activation mediated by TLR2, 
TLR4 and TLR9 but not TLR3 by sequestering the adaptor proteins MyD88 and MAL.  SIGIRR has 
been shown to inhibit MyD88-dependent signaling through its interactions with TRAF6 (TNF 
receptor-associated factor 6) and IRAK (Interleukin-1 receptor-associated kinase 1) (Wald et al. 
2003).  Thus, there is precedence for regulatory or inhibitory function among members of the 
TLR/IL-1 receptor superfamily. 
The biologic function of TLR10 may not be truly understood until a natural ligand has 
been discovered.  Nevertheless, since sustained TLR signaling is an underlying feature of a wide 
variety of chronic inflammatory conditions, including many autoimmune diseases and cancers 
(Mikacenic et al. 2013), the characterization of TLR10 as a broadly acting suppressor of TLR 
activation has far reaching therapeutic implications. 
  
 37 
 
Figures and Tables 
 
Figure 2.1. Stable TLR10 expression in U937 cells suppresses TLR-induced cytokine production. 
Parental U937 cells were transduced either with MMLV encoding FLAG-tagged TLR10 or an 
empty control MMLV.  Stably transduced cells were isolated after two weeks of selection under 
2 µg/ml Puromycin. (A) RT-PCR analysis of TLR10 expression in MMLV-U937 versus TLR10-U937 
cell lines (B) Surface staining of TLR10 transfected and control cells using an anti-FLAG antibody. 
Cells were gated on forward and side scatter characteristics. (C) TLR10-U937 and MMLV-U937 
control cells were differentiated for 48 hours in PMA. Cells were stimulated with the indicated 
agonist overnight, after which IL-6 was measured in cell-free supernatants using a paired-
antibody ELISA and (D) type-1 IFN was measured using an ISRE-L929 luciferase reporter assay. 
Luciferase activity was normalized to that of unstimulated MMLV control cells. Error bars 
represent the standard deviation of three independent samples and statistical analysis was 
performed using two-tailed paired Student’s t test. * p<0.01 
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Table 2.1. Differentially-regulated genes in stably transfected TLR10-U937 cells. TLR10-U937 
and MMLV-U937 control cells were differentiated for 48hrs in PMA and stimulated with 50 
ng/ml PAM3CSK4 for 4 hrs. RNA was isolated and analyzed by real-time PCR for message levels of 
selected of inflammatory genes. Data represent a subset of the 84 genes tested in the array 
that, after normalization to house-keeping genes (last 5 rows), showed greater than 2-fold 
difference between TLR10 and MMLV control cells. 
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Figure 2.2. TLR10 Suppresses PAM3CSK4-induced Cytokine Production in Stably Transfected 
U937 cells. TLR10-U937 and MMLV-U937 control cells where differentiated for 48hrs with PMA 
and stimulated overnight with varying concentrations of PAM3CSK4 as indicated. (A) IL-6 and (B) 
TNFα were measured in cell-free supernatants using a paired-antibody ELISA. Error bars 
represent the standard deviation of three independent samples and statistical analysis was 
performed using two-tailed paired Student’s t test. * p<0.01 
  
 
 40 
 
  
Figure 2.3. TLR10 suppresses phosphorylation of MAPKs and degradation of IκB.  TLR10-U937 
and MMLV-U937 control cells were stimulated with either (A) 50 ng/mL PAM3CSK4, (B) 50 ng/mL 
LPS or (C) 50 µg/mL polyI:C.  Cell lysates were analyzed by immunoblotting for the indicated 
signaling targets.  Data are representative of at least three independent experiments. 
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Figure 2.4. TLR10 suppresses both MyD88 and TRIF signaling. HEK293T cells were co-
transfected with the indicated TLR construct and either (A and C) MyD88 and an IL-8 promoter-
driven luciferase construct or (B and D) TRIF and an IFN-β-driven luciferase reporter construct. 
Results indicate fold induction of luciferase over empty vector after normalizing each sample for 
transfection efficiency using Renilla luciferase. Error bars represent the standard deviation of 
three independent samples and statistical analysis was performed using two-tailed paired 
Student’s t test. * p< 0.05, **p<0.005 
 
 42 
 
 
Figure 2.5. Dose-Dependent Suppression of MyD88 and TRIF Signaling by TLR10. HEK293T cells 
were co-transfected with varying concentrations of TLR10 and either (A) MyD88 and an IL-8 
promoter-driven luciferase construct or (B) TRIF and an IFN-β-driven luciferase reporter 
construct. Results indicate fold induction of luciferase over empty vector after normalizing each 
sample for transfection efficiency using Renilla luciferase. Error bars represent the standard 
deviation of three independent samples and statistical analysis was performed using two-tailed 
paired Student’s t test. * p< 0.05 
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Figure 2.6. Cell Surface Expression of TLR Constructs. HEK293T cells were transfected with the 
indicated FLAG-TLR or CD4-TLR construct and stained with either an anti-FLAG or anti-CD4 
antibody. FLAG-TLR and CD4-TLR constructs (black line) show surface expression of each 
construct compared to MMLV control cells (gray histogram). Cells were gated based upon 
forward and side scatter characteristics. 
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Figure 2.7. Generation of a TLR10 transgenic mouse under a constitutive CMV promoter 
(Performed by Xinyan Li). (A) Southern blot analysis of genomic DNA from 14 TLR10 positive 
founder mice with varying copy number insertions. (B) Reverse transcriptase dependent 
detection of FLAG-TLR10 in various tissues of a transgenic mouse. Western blots of (C) various 
tissues or (D) peripheral blood leukocytes from transgenic (tg) and non-transgenic (nc) mice 
using the anti-FLAG antibody to detect TLR10. FLAG-TLR10 migrates as a ~150 kDa band while a 
non-specific band appears at ~100 kDa.  
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Figure 2.8. Blood monocytes of TLR10 transgenic mice exhibit suppressed cytokine production 
in response to TLR agonists (Performed by Xinyan Li).  (A) Whole blood from either TLR10-
transgenic (tg) or non-transgenic (nc) littermate controls was stimulated with the indicated 
agonists and IL-6 release was measured in cell-free supernatants by ELISA.  (B) Whole blood was 
stimulated with LPS and IL-6 production was measured by intracellular staining in monocyte 
(CD11b+, Ly6G-) and neutrophil (CD11b+, Ly6G+) populations. Dot plot represents ungated cell 
populations. (C) Median fluorescent intensity (MFI) of IL-6 is shown relative to unstimulated 
cells. Error bars represent the standard deviation of three independent samples and statistical 
analyses were performed using two-tailed paired Student’s t test. * p<0.05, **p<0.01 
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Figure 2.9. Whole Blood Monocyte and Neutrophil Populations of TLR10 and Non-Transgenic 
Mice are Indistinguishable (Performed by Xinyan Li). Monocyte (CD11b+ and Ly6G-) and 
neutrophil (CD11b+, Ly6G+) populations from TLR10 transgenic (tg) and non-transgenic control 
mice (nc) were assayed by flow cytometry. A representative dot blot from each mouse is shown 
with averages and standard deviations derived from 6 transgenic mice and 6 non-transgenic 
mice. Dot plot represents ungated cell populations.  
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Figure 2.10. TLR10 transgenic mice exhibit suppressed responses to injected LPS but are not 
protected in a model of septic shock (Performed by Xinyan Li).  (A) Four TLR10-transgenic (tg) 
or four non-transgenic littermate controls (nc) were injected IP with 25 mg/kg of LPS. Blood was 
collected at 1 hr and 4 hrs post injection and serum TNF-α and IL-6 levels were measured using a 
paired antibody ELISA. Serum type-I IFN levels were measured using the ISRE-L929 reporter line. 
Error bars represent the standard deviation of at least three independent mice and statistical 
analysis was performed using one-tailed student’s t-test. * p<0.05.  (B) Six TLR10-transgenic (tg) 
and seven non-transgenic (nc) mice were injected IP with 25 mg/kg LPS and monitored for 
survival with results plotted in Kaplan-Meier format. 
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Figure 2.11. Anti-TLR10 antibody inhibits TLR-induced activation of peripheral blood 
mononuclear cells (Performed by Nicholas Hess). Human peripheral blood mononuclear cells 
from two separate donors were pre-incubated with either an anti-TLR10 antibody or isotype 
matched control antibody prior to stimulation with the indicated agonist for 24 hrs. Cell-free 
supernatants were collected and IL-6 and TNFα production was assayed using an antibody-
paired ELISA. Error bars represent standard error of the mean of three intra-donor replicates 
and statistical analysis was performed using the Holm-Sidak T-test assuming equal population 
scatter. * p<0.05; ** p<0.01 
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CHAPTER 3 
THE EXPRESSION PATTERN OF TOLL-LIKE RECEPTOR 10 ACROSS THE B CELL LINEAGE 
Abstract 
 Toll-like receptors (TLR) are type I transmembrane receptors that play a vital role in 
the recognition of invading microbes and endogenous danger signals.  They serve to initiate the 
inflammatory and healing response, as well as to aid in the induction of signaling events 
required for adaptive immunity.  These sentinel receptors are thus widely expressed in a variety 
of tissues.  Indeed, investigators have detected at least one member of the TLR family in virtually 
all tissues of the body, with expression of all ten TLR members detected in immune tissues such 
as the spleen and peripheral blood (Zarember and Godowski 2002).  Despite the widespread 
nature of TLR expression, studies by several labs have uncovered unique expression profiles of 
certain TLRs that have provided important clues to their respective functions (Aderem and 
Ulevitch 2000; Beutler and Rietschel 2003; Dasari et al. 2005; Zarember and Godowski 2002). 
 While numerous investigators have studied the expression of TLR10 mRNA in various 
cell populations (Bell et al. 2007; Bourke et al. 2003; Chuang and Ulevitch 2001; Hasan et al. 
2005), the study of TLR10 protein expression has been limited in large part by the lack of a 
reliable commercially available antibody.   We report here the generation of a monoclonal 
antibody specific for human TLR10 and subsequent studies using this reagent to study the 
expression of human TLR10 in peripheral blood, bone marrow, and tonsil tissue samples.  Such 
studies have been successful in defining the extracellular and intracellular expression pattern of 
TLR10, shedding light on the putative role of this receptor in immune cells. 
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Introduction 
Members of the TLR family have classically been characterized as innate immune 
pattern recognition receptors that serve the role of initiating the inflammatory response to 
infection.  However, in recent years, researchers have shed new light on the role of such 
receptors in initiating adaptive immunity as well.  Apart from the role of TLRs and other pattern 
recognition receptors in initiating antigen presentation in sentinel cells, mounting evidence exist 
that B cell intrinsic TLRs play a vital role in class switch recombination and robust humoral 
responses (Meyer-Bahlburg, Khim, Rawlings 2007; Nemazee et al. 2006; Pasare and Medzhitov 
2005).  Generally, TLR expression in B cells has been shown to enable these cells to become 
activated and proliferate in response to conserved microbial agonists (Bohnhorst et al. 2006; 
Ganley-Leal, Liu, Wetzler 2006; Gerondakis, Grumont, Banerjee 2007; Mansson et al. 2006; 
Pasare and Medzhitov 2005), but the physiological role of TLRs in B cell biology is also evidenced 
by numerous pathologies including systemic lupus erythematous, a situation where 
autoimmune antibody responses to self-DNA has been linked dual engagement of the B cell 
receptor together with TLR7, 8, and 9 agonists (Lau et al. 2005; Leadbetter et al. 2002; Rifkin et 
al. 2005). 
The TLR10 gene was first cloned in 2001, and investigators at that time used RT-PCR 
analysis to confirm the expression of TLR10 mRNA in a variety of tissues including spleen, lymph 
node, thymus, and tonsil (Chuang and Ulevitch 2001).  Several studies since that time have 
reported expression of the TLR10 message in a variety of immune cells, including regulatory T 
cells, B cells, plasmacytoid dendritic cells (pDC), eosinophils, neutrophils, Langerhans cells, and 
keratinocytes (Bell et al. 2007; Bourke et al. 2003; Flacher et al. 2006; Hasan et al. 2005; Mempel 
et al. 2003; Nagase et al. 2003).  The expression of TLR10 in B cell lineages appears to be 
regulated during B cell differentiation and maturation. TLR10 message is detected in both naïve 
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B cells and memory B cells, but TLR10 levels are much higher in memory B cells (Bernasconi, 
Onai, Lanzavecchia 2003; Weller et al. 2012).  TLR10 mRNA is undetectable, however, in 
terminally differentiated plasma cells (Dorner et al. 2009). TLR10 expression is also regulated 
upon stimulation. For example, when resting human tonsillar B lymphocytes were stimulated 
with CpG, B cell mitogen SAC, anti-BCR or anti-CD40, TLR10 expression is transiently upregulated 
(Bernasconi, Onai, Lanzavecchia 2003; Bourke et al. 2003).  The precise role of TLR10 in these 
various cell populations has yet to be elucidated, and while a number of labs have investigated 
the expression of TLR10 in multiple cell types, these experiments have relied exclusively on 
TLR10 mRNA expression due to the lack of a reliable commercially available TLR10 monoclonal 
antibody.   
 
Materials and Methods 
Antibodies and Reagents 
 Antibodies specific for CD3, CD19, CD27, and CD38 and their respective isotype 
controls were purchased from BD Biosciences (San Jose, CA).  Monoclonal antibodies against the 
extracellular domain of recombinant human TLR10 were produced in house.  One clone, 
3C10C5, is commercially available from numerous vendors.  Clone 5C2C5 was also used in this 
study where indicated.  The isotype control antibody used was MOPC-21, a murine IgG1 with no 
known specificity (BioLegend, San Diego, CA).  For cell culture media, RPMI 1640 was 
supplemented with 10% Fetal Bovine Serum, 2 mM glutamine and 1X non-essential amino acids.  
 
Monoclonal Antibodies to TLR10 (Dr. Yue Guan) 
Our lab has recently developed a monoclonal antibody that binds the extracellular 
domain of TLR10.  In work performed by Dr. Yue Guan, purified and properly folded TLR10 
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extracellular domain comprising amino acids 20-474 expressed in HEK 293F cells as a soluble 
protein was used as an immunizing antigen to generate antisera from five BALB/c mice.  
Antisera were subsequently screened for specific reactivity to microtiter plates coated with 
purified TLR10 by ELISA.  Splenocytes from an individual mouse with the most reactive 
antiserum were fused with myeloma cells to produce hybridomas.  The resulting hybridomas 
were then further screened for secretion of anti-TLR10 antibodies by ELISA.  Antibodies that 
cross-reacted with TLR1, which shares high sequence similarity with TLR10, were excluded, 
resulting in 52 hybridomas with TLR10 specificity.  17 of these hybridoma supernatants were 
found to display specific reactivity to surface-expressed FLAG-TLR10 in HEK293T cells using flow 
cytometric analysis, and 5 of the clones that displayed strong immunostaining ability were 
subsequently subcloned by limiting dilution.  This resulted in 15 individual subclones which 
exhibited specificity for surface-expressed TLR10 but no cross-reactivity to TLR1.  The 15 
subclones were further characterized as mIgG1 subclass with kappa light chain.  These subclones 
were confirmed to have the ability to recognize overexpressed surface TLR10 in the HEK293T 
system, with specificity for TLR10 and superior sensitivity compared to that of anti-FLAG 
antibody (data not shown).  Clone 3C10C5 has since been commercially licensed and is available 
through numerous vendors. 
 
Peripheral Blood Mononuclear Cells 
 For experiments characterizing the expression of TLR10 in peripheral blood immune 
cells, healthy, non-pregnant blood donors over the age of 18 were recruited from the University 
of Illinois at Urbana/Champaign.  Donors were asked to complete a brief survey indicating age, 
sex, and racial background.  Informed consent was obtained from all participants before 
inclusion in this study in accordance with an Institutional Review Board-approved protocol. 
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Human peripheral blood mononuclear cells (PBMC) were isolated from venous blood of healthy 
consenting adult donors via density gradient centrifugation according to manufacturer’s 
instructions.  Briefly, whole blood was diluted in room temperature Leukoctye Isolation Buffer 
(1X PBS, 2 mM EDTA, 2% FBS), slowly layered onto Ficoll-Paque (1.077 g/L) (GE-Healthcare, 
Pittsburgh, PA) and centrifuged for 20 minutes at 900 x g.  The resultant buffy coat was then 
removed and washed twice with ice-cold PBS.  
 
Peripheral Blood B cells 
 Peripheral blood B lymphoctyes were isolated from the PBMC buffy coat by negative 
selection according to manufacturer’s instructions using the Human B cell Isolation kit II 
(Miltenyi Biotec, San Diego, CA).  Briefly, 1x107 PBMCs were incubated with biotin-conjugated 
antibody cocktail solution containing antibodies against CD2, CD14, CD16, CD36, CD43, and 
CD235a to bind all non-B cells and subsequently incubated with anti-biotin magnetic 
microbeads.  The solution was then passed through a magnetic separation column from which 
flow through was collected containing untouched B cells.  B cell purity was ascertained as 
greater than 95% by CD19 staining (data not shown).   
 
Tonsillar B cells 
 To assess TLR10 expression at varying stages of B cell activation in the germinal center 
reaction, human tonsillar tissue was obtained from surgical discards of non-malignant 
individuals from Carle Foundation Hospital, Urbana, IL.  Tonsillar mononuclear cells were 
obtained by mechanical homogenization (Johnston, Sigurdardottir, Ryon 2009).  Untouched 
tonsillar B cells were obtained using RosetteSep immunodensity isolation according to 
manufacturer’s instructions (Stemcell Technologies, Vancouver, Canada).  Briefly, human RBCs 
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are preincubated with an antibody cocktail containing antibodies with specificity for CD2, CD3, 
CD16, CD36, CD56, CD66b, and glycophorin A on RBCs.  These heterologous RBCs are then 
combined with the tonsil mononuclear cells, forming tetrameric antibody complexes with non-B 
cells.  The solution is then overlayed over Ficoll-Paque, as previously described, and untouched 
purified B cells are left in the buffy upon density gradient centrifugation. 
 
Bone Marrow B cells 
 Cryopreserved bone marrow mononuclear cells isolated from whole bone marrow 
from five individual donors were purchased from Lonza (Walkersville, MD).  Cells were thawed 
and subsequently handled according to manufacturer’s suggestions.  Briefly, cells were flash 
thawed in a 37 degree water bath, washed, and resuspended in warm RPMI 1640 media 
supplemented with 10% FBS.  Cells were subsequently counted and assessed for viability before 
preparation for immunostaining and flow cytometric analysis. 
 
Immunostaining and Flow Cytometry 
 Peripheral blood mononuclear cell staining was performed on 2-3 x 105 cells per 
treatment.  Cell surface expression of endogenous TLR10 was measured using monoclonal 
antibody clone 3C10C5.  To minimize Fc receptor-mediated nonspecific antibody binding, 10% 
rabbit serum was included in the flow cytometric staining buffer in all wash and incubation 
steps.  A three-step staining protocol was used for signal amplification and performed to detect 
surface TLR10 on primary cells.  This procedure involved incubation of cells with anti-TLR10 
primary antibody at a concentration of 20 µg/ml, followed by biotinylated donkey anti-mouse 
IgG (Jackson Immunoresearch, West Grove, PA), and finally with Alexa 647-conjugated 
streptavidin (ThermoFisher Scientific, Waltham, MA).  For co-staining of surface TLR10 and other 
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cell surface markers, a subsequent incubation with FITC-conjugated antibodies was performed 
following TLR10 staining.  Flow cytometric analysis was performed on a BD FACS Canto II Flow 
Cytometer operated by the Roy J. Carver Biotechnology Center and data were analyzed using 
FCS Express software.  For intracellular staining, cells were first stained for any extracellular 
markers followed by fixation. Cells were then incubated in permeabilization buffer (flow buffer 
containing 0.1% saponin) for 30 min at room temperature. Cells were then washed and 
resuspended in 100 μL of permeabilization buffer containing labelled primary antibody followed 
by washing. 
 
Results 
TLR10 is Expressed in Peripheral Blood and Bone Marrow CD19+ B cells  
While numerous investigators have reported TLR10 mRNA expression in a variety of 
immune cells, the most convincing studies have isolated TLR10 expression to the B cell lineage.  
However, the surface expression profile of endogenous human TLR10 protein has yet to be 
reported, likely due to the lack of reliable reagents for flow cytometric study.  Given the 
preponderance of RT-PCR data suggesting the expression of TLR10 in B cell lineages, we sought 
to validate these findings by investigating surface expression of TLR10 in peripheral blood, bone 
marrow, and tonsillar tissue from multiple donor samples.  To investigate the surface expression 
of TLR10 in immune cells, total blood leukocytes were stained with APC-conjugated anti-TLR10 
mAb, developed as previously described in Materials and Methods.  A subpopulation of cells 
with high TLR10 staining was found to correspond to cells gated on the lymphocyte gate, but not 
the monocyte or granulocyte gate, based on forward and side scatter.  Cells were subsequently 
co-stained either with FITC-labeled anti-CD19 antibody (a marker of B cells), or a FITC-labeled 
anti-CD3 antibody (a marker of T cells).  Co-staining analysis found that TLR10 expression 
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coincided with CD19 expression, but not with CD3, giving strong evidence that TLR10 surface 
expression is found exclusively in the B cell lineage in peripheral blood leukoctyes (Fig. 3.1). 
 We next sought to analyze the donor-to-donor variability in TLR10 expression.  To 
accomplish this, peripheral blood mononuclear cells were obtained from ten different donors 
and stained with anti-CD19 and anti-TLR10, or isotype control.  As shown in Figure 3.2, TLR10 
correlates well with CD19 expression in all ten donors, with little donor-to-donor variability in 
the subjects studied.  Notably, TLR10 expression correlated directly with CD19, and there was no 
measurable TLR10 expression in CD19- cells, suggesting that TLR10 is exclusively expressed in 
cells of B cell lineage. 
 The close correlation of TLR10 with CD19 expression led us to analyze the expression 
of TLR10 in hematopoietic cells residing in bone marrow.  CD19 is well-established as marker of 
the B cell lineage early on in hematopoiesis, beginning at the progenitor stage.  To answer the 
question of whether TLR10 expression continued to coincide with CD19 along various stages in B 
cell maturation, human bone marrow mononuclear cell samples were purchased from Lonza 
(Basel, Switzerland) and analyzed for CD19 and TLR10 coexpression.  Cells were recovered and 
subsequently stained for TLR10 using the triple staining protocol described in Materials and 
Methods and co-stained with anti-CD19-FITC.  As shown in Figure 3.3, TLR10 surface expression 
correlates with CD19 expression in five individual bone marrow samples, revealing that TLR10 
again correlates with CD19 in the progenitor bone marrow population.  These findings indicate 
that TLR10 is co-expressed with CD19.  Importantly, there was not a significant number of 
CD19+ cells that did not express TLR10, indicating that, like CD19, TLR10 expression is turned on 
as early as the pro-B cell maturation stage (Fig. 3.4). 
 
 
 59 
 
TLR10 Expression is Upregulated in Memory B cells 
 Next, we sought to investigate variations in TLR10 surface expression in different stages 
of B cell activation.  Memory B cells are a unique subset of circulating B cells that are formed 
following a primary infection.  Upon activation by BCR and co-stimulatory molecule stimulation, 
most B cells respond by undergoing differentiation to the antibody-secreting plasma cell stage.  
A subset, however, are known to differentiate into memory B cells that continue to circulate in 
peripheral blood, and can be stimulated to differentiate to plasma cells months to years later 
upon a second exposure.  Indeed, memory B cells isolated in vitro are able to proliferate with 
stimulation from TLR agonists alone, without the need for BCR crosslinking, providing a 
functional correlate with the unique expression pattern of TLRs in B cells (Bernasconi, Onai, 
Lanzavecchia 2003; Boeglin et al. 2011; Chiron et al. 2008).  Bernasconi et al. had reported that 
TLR9 and 10 message levels were increased in memory versus naïve B cells.  We therefore 
investigated this finding by looking at the presence of TLR10 on the cell surface.  For our studies, 
peripheral blood B cells were isolated by negative selection and co-stained with anti-CD27 and 
anti-TLR10 antibodies.  We found that endogenous human TLR10 is more highly expressed in 
CD27+ memory B cells upon co-staining (Fig. 3.5).  Importantly, CD27- and CD27+ peripheral B 
cells both showed a significant level of TLR10 expression, however, the CD27+ subset exhibited a 
two-fold increase in TLR10 expression.  This finding validates the findings of Bernasconi et al., 
and indicates a possible role for extracellular surface TLR10 function in memory B cells.   
 
TLR10 Expression is Progressively Downregulated at Advanced Stages of B cell Activation and 
is Significantly Attenuated at the Plasmablast Stage 
Because numerous stages of B cell activation exist in lymphoid tissue, and these 
subtypes have been shown to respond differently to agonist-induced differentiation and 
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proliferation, we were interested in investigating the TLR10 expression profile within B cell 
subtypes in lymphoid tissue.  We further investigated TLR10 expression along the B cell lineage 
by co-staining TLR10 with the B cell activation surface marker CD38, which has been found to be 
specific to different transitional stages of B cells within tonsil tissue (Liu and Arpin 1997; 
Mansson et al. 2006).    
To this end, human tonsillar B cells were isolated by a modified rosetting technique that 
allowed for the isolation of a pure population of tonsillar B cells.  These cells were subsequently 
co-stained with anti-CD19, anti-TLR10 antibody, and anti-CD38, a marker of B cell activation in 
the germinal center reaction and progression to the plasmablast stage (Kjeldsen et al. 2011).  
CD19+CD38LO tonsil mononuclear cells exhibited the highest level of TLR10 expression, while 
CD19+CD38INT and CD19+CD38HI populations exhibited progressively lower levels of surface 
TLR10 expression (Fig. 3.6). Thus, to our surprise, these data suggest that TLR10 expression is 
decreased along progressive stages of B cell activation within lymphoid tissue.   TLR10 
expression decreases as CD38 expression increases, suggesting that TLR10 expression is 
attenuated as B cells progress into the plasmablast stage.  Furthermore, comparison with bone 
marrow cells with negative CD19 expression indicates that TLR10 is turned off at the plasma cell 
stage of activation as well (Fig. 3.4).  These findings suggest a putative role for TLR10 function in 
the context of naïve B cell activation, which becomes turned off as B cells transition to the 
plasmablast and plasma cell stage.  
 
Discussion 
 While other members of the TLR family have been extensively studied at both the 
expression and functional level, TLR10 remains an orphan TLR with no established ligand 
recognition or signaling function.  Studies to elucidate the function of TLR10 are severely 
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hampered by the lack of a functional TLR10 gene in mice; however, we and others have recently 
presented evidence that TLR10 may serve as a negative regulator of inflammatory responses 
(Ammerdorffer et al. 2016; Jiang et al. 2016; Oosting et al. 2014).  TLR10 is expressed in humans 
and in multiple primate and other mammalian species (Mikami et al. 2012), making the lack of a 
functional gene in mice an unresolved anomaly.  To gain further insight into TLR10 function, our 
goal was to fully characterize the expression of endogenous TLR10 in human immune cells.  
Previous studies had isolated TLR10 mRNA expression to lymphoid tissue, with particularly high 
expression in the B cell lineage (Chuang and Ulevitch 2001; Hasan et al. 2005).  Additional 
studies have since discovered high levels of mRNA in primary B cells and immortalized lines 
(Bourke et al. 2003; Hornung et al. 2002; Mansson et al. 2006).  In one recent study investigating 
the levels of TLR10 protein expression on the cell surface, researchers did report the 
observation that CD27+ peripheral blood memory B cells expressed higher levels of TLR10, 
suggesting a role for TLR10 in the development and maintenance of this cell population (Weller 
et al. 2012).  In our present report, we present the first extensive characterization of 
endogenous cell-surface TLR10 expression in the B cell lineage in primary human lymphoid 
tissue, including peripheral blood, tonsil, and bone marrow. 
 While the results of our investigation of the presence of TLR10 on the B cell surface 
largely parallel the previous findings of TLR10 mRNA expression using RT-PCR techniques, co-
staining experiments with the B cell marker CD19 were able to more precisely correlate TLR10 
expression with that of CD19 in peripheral blood, as well has in bone marrow.  Our results 
suggest that, like CD19, TLR10 expression is turned on as early as the progenitor B cell stage in 
hematopoietic development.  Our results cause us to speculate on the possibility that TLR10 
expression may be under the same transcriptional control as CD19, namely by the transcription 
factor Pax5, a known regulator of B cell development.  That numerous proximal and distal 
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putative Pax5 binding sites exist within the promotor sequence of the TLR10 lends further 
support to this possibility (data not shown).  Furthermore, and again in close parallel with CD19, 
surface TLR10 expression is abrogated during plasma cell differentiation, an occurrence that 
may be due to a change in a splice variant of TLR10, one of which results in a TLR10 protein that 
lacks the signal sequence required from membrane trafficking.  Intracellular staining 
experiments performed by Nick Hess in the lab have shown that TLR10 expression may change 
from extracellular to an intracellular location during the transition to the plasma cell stage (data 
not shown).  Given the published evidence from several studies that have failed to detect TLR10 
mRNA in bone marrow plasma cells (Bohnhorst et al. 2006; Bourke et al. 2003), the presence of 
TLR10 in intracellular compartments is likely due to an internalization of surface TLR10, rather 
than a product of new protein synthesis. 
 Another important finding from these studies relates to the expression of TLR10 
during the germinal center reaction and the important process of B cell activation.  Given the 
rise in appreciation of the role of B cell intrinsic innate immune receptors in activating and 
maintaining a robust humoral immune response, it is very interesting that TLR10 expression 
appears highly coordinated with the various stages of B cell activation.  In the context of the 
germinal center reaction in tonsillar lymphoid tissue, TLR10 expression appears to be 
downregulated as B cells become progressively activated.  This trend continues as cells enter the 
plasmablast stage in lymphoid tissue, finally resulting in undetectable surface TLR10 protein on 
bone marrow plasma cells.  Before B cells enter the plasmablast fate, however, a subpopulation 
of activated B cells undergo differentiation to memory B cells that are maintained in peripheral 
blood.  Interestingly, the surface expression of TLR10 protein, in support of the findings of 
Weller et al., was significantly enhanced in this cell population compared to naïve peripheral 
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blood B cells, lending credence to the possibility that surface TLR10 plays an active role in the 
development of maintenance of this cell population. 
 Given the evidence of TLR10 as a negative regulator of pro-inflammatory signaling 
presented in Chapter Two, it is interesting to speculate on the potential role of TLR10 as a 
negative regulator of B cell function as well.  The precise control of TLR10 in hematopoiesis, as 
well as its progressive reduction along stages of B cell activation and increased expression of 
surface TLR10 in memory B cells certainly create multiple possibilities and avenues of inquiry 
regarding the role of TLR10 in these cells.  These findings, along with numerous studies 
implicating TLR10 polymorphisms in various autoimmune and neoplastic diseases, continue to 
shed greater light on the physiological impact of TLR10 on the immune system (Lazarus et al. 
2004; Purdue et al. 2008; Zhou et al. 2006). 
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Figures 
 
 
 
 
 
Figure 3.1. TLR10 is Expressed on peripheral blood B lymphocytes.  (A) Representative dot plot 
of peripheral blood cells. Granulocytes and monocytes were gated by forward and side scatter 
characteristics. Lymphocytes are further separated by CD3 and CD19 co-staining (shown in 
boxes) to differentiate T cells and B cells respectively. (B) Representative histograms of each cell 
population showing TLR10 expression (black line) compared to an isotype control antibody 
(shaded grey). A tertiary stain was used for both TLR10 and isotype control antibodies.   
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Figure 3.2. TLR10 correlates with CD19 expression in various donors.  (A) Peripheral blood 
mononuclear cells were obtained from 10 different donors and stained with anti-CD19 and anti-
TLR10 or isotype control.  CD19 expression correlates with that of TLR10.  TLR10 staining was 
performed using a triple labeling procedure involving incubation with anti-TLR10 mAb, a biotin-
conjugated donkey anti-mouse secondary, and subsequent incubation with streptavidin-
Alexa647 and antiCD19-FITC as described in Materials and Methods. (B) Composite data 
representing cells with CD19 and TLR10 co-expression for 10 donors are shown as percentage of 
the total cell PBMC population.  Error bars represent SEM. 
A 
B 
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Figure 3.3.  TLR10 surface expression in bone marrow mononuclear cells correlates with CD19 
expression.  (A) Flow cytometric analysis of human bone marrow mononuclear cells from 5 
different samples co-stained with anti-CD19 and anti-TLR10.  Scatterplots on the left column 
represent cells stained with isotype control, whereas right column represents cells stained with 
anti-TLR10 according to the triple staining protocol described in Materials and Methods.  Rows 
represent individual donors. (B) Composite data for 5 donors representing correlation of CD19 
and TLR10 expression as percentage of the total mononuclear cell population.  Error bars 
represent SEM. 
 
A 
B 
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Figure 3.4. Surface expression of TLR10 is abrogated in marrow plasma cells.   
(A) Representative dot plot of bone marrow cells co-stained with CD19 and CD38. Populations 
are highlighted in boxes; immature B cells (right box), plasma cells (upper box) and non B cells 
(unboxed cells). (B) Representative histogram of each cell populations showing TLR10 expression 
(black line) compared to an isotype control antibody (shaded gray). (C) Bar graph representing 
the difference in median fluorescent intensity (MFI) between TLR10 and isotype from 4 donors. 
A tertiary stain was used for both TLR10 and isotype antibodies. Error bars represent SEM. 
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Figure 3.5.  TLR10 is more highly expressed in peripheral blood memory B cells. (A) 
Representative dot plot of peripheral blood B cells isolated by negative selection and stained 
with CD27. B cell populations were divided by CD27 expression (shown in boxes) to represent 
memory B cells (upper box) and naïve B cells (unboxed). (B) Representative histograms of each B 
cell population shown as TLR10 staining (black line) compared to an isotype control antibody 
(shaded gray). (C) Bar graph representing the ΔMFI between TLR10 and isotype antibodies from 
3 donors. A tertiary stain was used for both TLR10 and isotype antibodies. Error bars represent 
SEM. 
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Figure 3.6. Germinal Center Activation is Negatively Correlated with TLR10 Expression.              
(A) Representative dot plot of tonsillar tissue co-stained with CD19 and CD38. B cell populations 
were divided by CD38 expression (shown in boxes) to represent naïve germinal center B cells 
(bottom), centrocytes (middle) and plasmablasts (top). (B) Representative histograms of each B 
cell population shown as TLR10 staining (black line) compared to an isotype control antibody 
(shaded gray). (C) Bar graph representing the ΔMFI between TLR10 and isotype antibodies from 
3 donors. A tertiary stain was used for both TLR10 and isotype antibodies. Error bars represent 
SEM. 
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CHAPTER 4 
TOLL-LIKE RECEPTOR 10 IS A B CELL-INTRINSIC SUPPRESSOR OF 
ADAPTIVE IMMUNE RESPONSES 
Abstract 
Emerging evidence over the past 20 years has shed new light on the important role of 
Toll-like receptors (TLR) and other innate immune receptors in tailoring the adaptive arm of the 
immune response.  While this role is best appreciated in the context of antigen presentation, 
lymphocyte-intrinsic TLR engagement also contributes to adaptive immune responses.  Several 
TLR agonists are known B cell mitogens and B cell-intrinsic TLR activation is known to promote 
proliferation, antibody production, and class switch recombination (CSR).  TLR10 has been 
shown previously to be preferentially expressed on B lymphocytes, but despite thousands of 
publications on TLRs, the ligand recognition and signaling capabilities of TLR10 remains 
unknown.  We report herein that antibody-mediated engagement of TLR10 on the surface of 
human B lymphocytes suppresses B cell proliferation, cytokine production and signal 
transduction.  Interestingly, TLR10 was observed to inhibit responses to a variety of B cell 
stimulatory signals including those from the B cell receptor (BCR), CD40 and other TLRs.  To 
overcome the fact that TLR10 is a naturally disrupted pseudogene in mice, we also created a 
transgenic mouse model using a BAC clone encoding human TLR10 in the context of its native 
promoter.  TLR10 transgenic mice express the receptor in lymphoid tissue with clear expression 
in B lymphocytes but without measurable effects on B cell development.  Compared to non-
transgenic littermate controls, TLR10 transgenic mice exhibit diminished antibody responses 
following vaccination with either T-independent or T-dependent antigens with marked effects 
on CSR.  Finally, adoptive transfer of splenic B cells from TLR10 transgenic mice into B cell 
deficient µMT mice revealed that the suppressive effects on antigen-specific humoral immune 
75 
 
responses are B cell-intrinsic.  Our results demonstrate that TLR10 has a functional role within 
the B cell lineage that is distinct from that of other TLR family members and point to a 
potentially novel therapeutic target for certain B cell lymphomas and also autoimmune diseases 
characterized by dysregulated B cell activity. 
 
Introduction 
Toll-like receptors (TLRs) are members of a class of so-called pattern recognition 
receptors (PRRs) that classically serve to mediate host recognition of pathogen-associated 
molecular patterns (PAMPs) and initiate immediate signaling events that result in the 
production of chemokines and cytokines integral to the induction of the immune response.  
Members of the TLR family are type I transmembrane receptors and are comprised of a solenoid 
leucine-rich repeat extracellular domain responsible for ligand recognition and a 
Toll/Interleukin-1 Receptor (TIR) intracellular signaling domain (Kawai and Akira 2010).  Ligand 
binding results in dimerization of individual TLRs, which allows for homotypic interactions 
between their TIR signaling domains.  This results in the recruitment of either MyD88 or TRIF, 
TIR-containing proximal signaling molecules that upon oligomerization serve as a molecular 
scaffold that recruits additional signaling adaptors ultimately resulting in the generation of a 
pro-inflammatory signaling cascade.  This signaling culminates in activation of NF-κB, AP-1 
and/or IRF proteins, transcription factors that drive pro-inflammatory gene expression (Gay et 
al. 2014; Kawasaki and Kawai 2014; Lin, Lo, Wu 2010).  In addition to the well-established role of 
TLR signaling in the context of innate immune activation, growing evidence over the past 15 
years suggest that TLRs also play an active role in the initiation and maintenance of adaptive 
humoral immunity (Browne 2012; Meyer-Bahlburg, Khim, Rawlings 2007; Pasare and Medzhitov 
2005).  Additionally, lymphocyte-intrinsic TLR signaling has been heavily implicated in the 
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propagation of the memory B cell population, autoantibody production, and the capacity of B 
cell lymphomas and myelomas to proliferate (Bohnhorst et al. 2006; Bourke et al. 2003; Chiron 
et al. 2008; Dorner et al. 2009; Ngo et al. 2011; Weller et al. 2012). 
B cell activation is highly regulated and classically requires two independent signals from 
the BCR, as well as co-stimulation by helper T cells through its interaction with CD40.  Indeed, 
the induction of an anergic state in immature B lymphocytes is thought to be mediated by 
transient stimulation of the BCR without a co-stimulatory signal (Yarkoni, Getahun, Cambier 
2010).  The initial stages of B cell activation begin with the binding of the antigen to the BCR, 
resulting in endocytosis, processing and presentation of peptide antigen on MHCII, and finally 
recognition of the cognate antigen by helper T cells, which provide a costimulatory signal via the 
CD40/CD40L interaction.  Importantly, B cell activation has been known to occur without the 
need for T cell help through activation by polymeric antigens that crosslink a threshold number 
of BCRs, or through antigens that have the capacity to stimulate B cell-intrinsic TLRs (Browne 
2012; Jeurissen, Ceuppens, Bossuyt 2004; Meyer-Bahlburg, Khim, Rawlings 2007; Pasare and 
Medzhitov 2005).  The involvement of TLR signaling in B cell biology is further highlighted in 
pathologic processes such as systemic lupus erythematosus (SLE), where the expression of 
nucleic acid sensing TLRs 7, 8, and 9 in B cells have been shown to be an important factor in the 
generation of anti-DNA complexes resulting in Type III hypersensitivity responses and 
complications stemming from systemic vasculitis (Groom et al. 2007; Lau et al. 2005; Rahman 
and Eisenberg 2006; Richez et al. 2011).  As presented in the preceding chapter, we and others 
have found a unique expression profile for endogenous human TLR10 within the B cell lineage.  
We have shown that TLR10 is expressed in B lymphocytes as early as the pro-B cell stage of 
hematopoietic development and correlates precisely with expression of CD19.  Interestingly, 
surface TLR10 expression is progressively diminished as B cells progress through the distinct 
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stages of B cell activation within lymphoid tissue.  Surface TLR10 expression is completely 
abrogated in terminally differentiated plasma cells residing in the bone marrow. 
The unique expression pattern of TLR10 and its close regulation through various stages 
of the germinal center reaction suggests that TLR10 may play an important function in B cell 
biology.  Of the ten TLRs expressed in humans, TLR10 remains an orphan member with no well-
established natural ligand or signaling capability.  Research on TLR10 has been hampered by the 
discovery that murine TLR10 is a pseudogene, disrupted by several deletions and retroviral 
insertions.  This situation prevents the use of traditional knock-out mouse models to assess 
TLR10 function.  Although TLR10 is a pseudogene in mice, the full length gene continues to be 
propagated in evolutionary history and is expressed in all other mammalian species that have 
been studied (Mikami et al. 2012; Roach et al. 2005).  TLR10 lies in tandem arrangement with 
TLRs 1 and 6 on chromosome 4, which are believed to have arisen from a gene duplication of an 
ancestral TLR (Roach et al. 2005).  Unlike other TLRs that are under purifying selection, this 
constrictive evolutionary pressure appears to be more relaxed in TLR10, which contains several 
amino acid substitutions in the conserved TIR domain (Mikami et al. 2012).  Previously, our lab 
has shown that similar to its close homologue TLR1, TLR10 has the capacity to heterodimerize 
with TLR2 to recognize triacylated lipopeptides and recruit MyD88, although no detectable pro-
inflammatory response was found (Guan et al. 2010).  Additionally, we and others have recently 
presented evidence that suggests a role of TLR10 as a negative regulator of pro-inflammatory 
signaling that is unique among members of the TLR family (Jiang et al. 2016; Oosting et al. 2014).  
The expression of TLR10 within the B cell lineage presented in Chapter Three led us to 
investigate TLR10 in the context of B cell responses.  In this chapter, I present experiments 
attempting to elucidate the precise role of TLR10 in the context of B cell activation and the 
humoral response. 
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Materials and Methods 
Reagents 
RPMI 1640 supplemented with 10% FBS, 2 mM glutamine and 1X non-essential amino 
acids was used for all cell culture. Anti-IgM and anti-mouse IgG antibodies were purchased from 
Jackson Immunoresearch (West Grove, PA). Anti-CD40 was purchased from R&D Systems 
(Minneapolis, MN). R848 and Class C CpG were purchased from Invivogen (San Diego, CA). 
Phospho-specific antibodies against p38 (clone D3F9), JNK (clone 81E11), Syk Y525/526 (C87C1), 
Akt S473 (D9E), and β-actin (clone 13E5) were purchased from Cell Signaling Technologies 
(Danvers, MA).  The isotype control antibody (clone MOPC-21) was purchased from BioLegend 
(San Diego, CA).  The anti-TLR10 antibody (clone 3C10C5) was created in-house, and is available 
commercially through numerous vendors. 
 
Human B cell Isolation 
Peripheral blood B cells were isolated first by density gradient centrifugation of whole 
blood over a Ficoll-Paque solution (GE Healthcare, Chicago, IL) at 1100xg for 10 min with no 
brake to obtain mononuclear cells (PBMC) from the buffy coat.  B cells were isolated from the 
PBMC using a MACS B-cell Isolation Kit II (130-091-151) according to the manufacturer’s 
instructions. Tonsillar tissue was obtained from surgical discards of routine tonsillectomies 
performed at Carle Foundation Hospital.  Tonsil mononuclear cells were obtained by 
homogenization and subsequent filtering through a 40 μM sieve.  Tonsillar B cells were 
separated by adding previously isolated human RBCs in a 50:1 ratio.  A RossetteSep (Stemcell 
Technologies, Vancouver, Canada) antibody cocktail was added and incubated for 15 min prior 
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to density gradient centrifugation over a Ficoll-Paque solution, in which the buffy coat consisted 
of isolated B cells. 
 
Flow Cytometry 
Approximately 2-4 x 106 cells/tube were blocked in Flow Buffer (1X PBS, 10% Rabbit 
Serum) for 30 min.  Cells were centrifuged and re-suspended in 100 μL of Flow Buffer. Primary 
antibody was added as suggested by the manufacturer, or at 10 μg/mL, and incubated for 30 
min. For TLR10 detection, an anti-mouse IgG1-Biotin Conjugate and Streptavidin-APC 
Conjugated antibody (Jackson Immunoresearch) were also utilized following the same labeling 
procedure as the primary antibody.  Cells were centrifuged and fixed by adding 300 μL of 4% 
paraformaldehyde for 15 min, after which they were re-suspended in 100 μL of Flow Buffer and 
analyzed on a BD FACS Canto II Flow Cytometer operated by the Roy J. Carver Biotechnology 
Center.  All steps were performed on ice.  
 
PCR Superarray 
RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instructions.  The cDNA was prepared with a 1:1 mixture of oligo-dT and random 
primers (Invitrogen, Carlsbad, CA), 1 μg of RNA and the Superscript III enzyme.  Reverse 
transcriptase negative samples were made by withholding Superscript III from the reaction 
mixture.  PCR was done using AmpliTaq Gold 360 Master Mix (Applied Biosystems, Foster City, 
CA).  Primers used for TLR10 (F -CAGTGGAACACTTTCAGATCC, R - CCAAGGGTGTGTTGTTAGC); 
HPRT1 (F - TGGGCTTACCTCACTGCTTT, R - CTAATCACGACGCTGGGACT).  For the PCR Superarray, 
total RNA was isolated after 24 hr of stimulation and sampled using a T cell and B cell Activation 
PCR Array (SA Biosciences, Qiagen, Hilden, Germany) according to manufacturer’s instructions.   
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Human B cell Stimulation Assays 
Isolated human B cells were pre-incubated with either an isotype control (20 μg/mL) or 
anti-TLR10 (20 μg/mL) antibody with the addition of a secondary anti-mouse IgG (20 μg/mL) 
antibody for 30 min prior to stimulation with αIgM (20 μg/mL), αCD40 (0.1 μg/mL), R848 (100 
ng/mL) or CpG (2 μg/mL).  After 24 hr stimulation, cell-free supernatants were assayed by ELISA 
using a MIP-1β antibody pair (Life Technologies, Carlsbad, CA) using a 1:20 dilution. Proliferation 
was assayed using an ELISA based BrdU detection kit (Roche, Basel, Switzerland).  In short, a 1X 
solution of BrdU was added to the cells.  After 24 hr, the supernatant was removed and the cells 
fixed to the plate.  Cells were then incubated with a HRP-conjugated-anti-BrdU antibody for 2 hr 
prior to washing and the addition of TMB for color detection at 450 nm.  
 
Human B cell Signaling 
Tonsillar B cells were pre-incubated with an isotype control or anti-TLR10 antibody as 
described earlier prior to stimulation.  After 15 min, cell lysates were collected in RIPA lysis 
buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1% NP-40 and 1 mM EDTA) supplemented with 
Halt protease and phosphatase inhibitor (ThermoFisher, Carlsbad, CA).  Equivalent amounts of 
protein lysate were loaded onto a SDS-PAGE gel, transferred to PVDF membranes and blotted 
against specific phospho-antibodies (Cell Signaling Technologies, Danvers, MA). 
 
Generation of TLR10 Transgenic Mice 
A constitutive human TLR10 knock-in mouse expressing the full-length human TLR10 
gene was generated by the UIUC Transgenic Facility.  The BAC clone #1148D18 containing the 
full coding region of TLR10 with its native promoter was purchased from Empire Genomics 
(Buffalo, NY).  BAC DNA was isolated with Qiagen’s Large Construct Kit with genomic DNA 
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removed by endonuclease digestion.  Approximately 80 μg of plasmid DNA was digested with 
100 units of BsrB1 and HF-Not1 to release a 16,584 bp fragment containing the full TLR10 
transcript along with ~4 kb of the upstream and ~3 kb of the downstream sequence.  Excised 
DNA was recovered with Qiagen’s Large Fragment Extraction Kit before continuing with the 
transgenic process, performed by the Roy J. Carver Biotechnology Center at the University of 
Illinois Urbana-Champaign.  Briefly, transgenic mice were generated by microinjection of the 
DNA transgene purified from a plasmid vector into one-cell mouse embryos followed by 
implantation into foster mice.  54 transgenic pups were received at 3 weeks of age and screened 
for TLR10 insertion by PCR.  Eleven of the transgenic pups were identified to carry the transgene 
of which 6 founders carried more than 10 copies of the transgene as determined by southern 
blot analysis.  Three lines were selected for further characterization of expression by RT-PCR and 
immunoprecipitation of TLR10 using tissues from a subset of mouse organs.  Line 5-1 was 
chosen for further experimental characterization because of its intermediate level of 
transcriptional and protein expression and its large litter size.  Genotyping of the mice was 
performed using For- CAGTGGAACACTTTCAGATCC and Rev-CCAAGGGTGTGTTGTTAGC primers.  
All mice used for experiments were between the ages of 4 – 12 weeks.  For consistency, only 
males were used in our experiments. 
 
Splenic B cell Isolation 
Murine splenocytes were isolated by manual disruption of the spleen in sterile PBS 
followed by passage of the solution through a 40 μM filter.  Mononuclear splenocytes were 
furthered purified by density gradient centrifugation on a Ficoll-Paque gradient.  B cells were 
isolated using the Stemcell Technologies EasySep Mouse B Cell Isolation Kit. 
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Murine B cell Stimulations 
Murine splenic B cells were isolated as described above and incubated at a 
concentration of 2-3 x 106 B cells/100 μL of media in BD Falcon tubes.  Prior to stimulation, cells 
were incubated in 10nM CFSE PBS (Life Technologies, Carlsbad, CA) in PBS for 20 min at RT in 
the dark.  Cells were then washed and re-suspended in media followed by stimulated with αIgM 
(20 μg/mL), αCD40 (1 μg/mL) or CpG (4 μg/mL). After 72 hr, cell-free supernatants were 
collected for analysis by an IL-6 Antibody Paired ELISA (Life Technologies) using a 1:4 dilution. 
Cell pellets were prepared for flow cytometry and analyzed on a BD FACS Canto II flow 
cytometer to measure CFSE fluorescence.  
 
Immunization & NP-Specific Antibody ELISA 
Age and sex matched mice were immunized with either 4-hydoxy-3-nitrophenylacetyl-
Chicken Gamma Globulin (NP(27)-CGG) or 4-hydroxy-3-nitrophenylacetyl Lipopolysaccharide 
(NP(7)-LPS) (BioSearch Technologies, Petaluma, CA) mixed in a 1:1 ratio with Imject Alum 
(ThermoScientific, Waltham, MA).  Each mouse received a 200 μL intra-peritoneal injection of 
NP(27)-CGG or NP(7)-LPS equal to 100 μg and 20 μg of antigen respectively.  Blood was collected 
from the submandibular vein and serum was collected prior to immunization as well as 7 and 14 
days after immunization.  NP-specific ELISA plates were prepared by coating NP(5)-BSA 
(BioSearch Technologies, Petaluma, CA) onto ThermoScientific Nunc plates at concentration of 
10 μg/mL in Coating Buffer B (4.3 g NaHCO3, 5.3 g Na2CO3, 1 L H2O) and incubated at 4 °C 
overnight.  Plates were then blocked in Assay Buffer (1X PBS, 2% BSA, 0.05% Tween 20) for 1 hr.  
Serum samples were diluted at 1:10,000 for IgM and IgG1 and 1:100 for IgG2b, IgG2c, IgG3 and 
IgA.  An 8-point standard curve was created by taking pooled undiluted serum from previous NP 
injections and creating serial dilutions starting at 1:50 or 1:5000 for each respective isotype.  
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Serum samples and standards were allowed to incubate for 1 hr.  Biotin-conjugated goat anti-
mouse detection antibodies (Southern Biotech, Birmingham, AL) specific to each isotype were 
added at 50 ng/mL and allowed to incubate for 1 hr.  Streptavidin-HRP (Jackson 
ImmunoResearch, West Grove, PA) was added at 0.1 μg/mL and incubated for 30 min before 
developing in an OPD solution.  Wells were washed in ELISA Wash Buffer (1X PBS, 0.05% Tween 
20) between each step and measured at an absorbance of 490 nm.  
 
Adoptive B cell Transfer 
Splenic B cells were isolated as described previously from groups of 5-9 male mice. 
Splenocytes were pooled for subsequent B-cell isolation and then re-suspended in sterile PBS at 
a concentration of 1 x 108 B-cells/mL.  A total of 200 μL, equaling 2 x 107 B cells was injected via 
intra-venous injection into the caudal tail vein of male μMT mice and allowed to colonize for 24 
hr before immunization.  To further boost the immune reaction, LPS was added to the NP(27)-
CGG immunizations equivalent to 5 μg LPS per mouse. 
 
Statistics 
All statistics were performed using the GraphPad Prism software. Significance was 
determined by a t-test using the Holm-Sidak method with an alpha of 5.0%.  
 
Results 
Identification of Endogenous Lymphocyte TLR10 Expression in Human Donors 
To first confirm that TLR10 is expressed on peripheral blood B cells from our set of 
human donors, whole blood was taken from healthy individuals and stained for TLR10 using a 
triple labeling procedure (see Materials and Methods).  A shift in the TLR10 fluorescence was 
84 
 
detected compared to an isotype control antibody in a small percentage of lymphocytes that 
were gated by their inherent forward and size scatter properties (Fig. 4.1a).  Since only a fraction 
of lymphocytes exhibited a TLR10 shift we further sub-divided the lymphocytes based on co-
staining with the T cell marker CD3 and the B cell marker CD19.  Co-staining revealed that only 
CD19 expressing cells exhibited a TLR10 shift confirming that TLR10 is only expressed on B-cells 
within the lymphocyte population (Fig 4.1b). 
 
TLR10 Cross-Linking Suppresses B cell Proliferation 
 The expression of TLR10 in B cells is indicative of a functional role for this receptor in 
this cell type.  Indeed, in studies presented previously, the presence of TLR10 on the B cell 
surface is tightly regulated and progressively decreases as B cell progress through the germinal 
center reaction.  With knowledge of tightly regulated TLR10 expression in the B cell 
compartment, we sought to explore the effect of antibody-mediated cross-linking of TLR10 on B 
cell activity.  To this end, resting CD19+ B cells were isolated by negative selection from 
peripheral blood mononuclear cells and stimulated with S. aureus Cowan strain (SAC), an 
established B cell mitogen.  We observed that an anti-TLR10 monoclonal antibody can 
significantly attenuate mitogen-induced B cell proliferative responses, presumably by cross-
linking the surface receptor.  Addition of a secondary anti-mouse F(ab)’2 enhanced the 
suppressive activity of anti-TLR10 mAb, likely by enhancing the crosslinking effect.  This 
represents the first evidence implicating endogenous human TLR10 as a functional modulator of 
B cell function (Fig. 4.2). 
We next used a variety of B cell activation outputs to investigate the effect of TLR10 
activation on B cell proliferative responses.  Robust B cell activation requires cross-linking of the 
B cell receptor, T cell help, and a third signal provided by TLR ligation.  Numerous reports in the 
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literature have shown that the proliferative capacity of circulating B cells in response to CD40 or 
BCR crosslinking is further enhanced by TLR co-stimulation (Bekeredjian-Ding et al. 2007; 
Boeglin et al. 2011; Mansson et al. 2006).  Given our recent findings that TLR10 may act as a 
global suppressor of MyD88 and TRIF signaling, we wished to test whether TLR10 would 
suppress B cell signaling and proliferative responses in response to various B cell activation 
conditions.  To investigate this possibility, we isolated peripheral blood B cells from six individual 
donors and treated them with either anti-TLR10 or isotype control antibody and then stimulated 
with a combination of B cell agonists, including anti-µ (to simulate BCR crosslinking), anti-CD40 
(to simulate the effect of T cell help), and the TLR7/8 agonist R848.  Proliferation was assessed 
after 96 hours by BrdU incorporation assay.  We observed that TLR10 ligation suppressed 
proliferative responses to TLR co-ligation with BCR activation (Fig.4.3).  To our surprise, 
however, the suppressive activity of TLR10 also extended to the proliferative response induced 
by BCR/CD40 co-stimulation, suggesting that TLR10 signaling induces a global suppression of B 
cell responses beyond that of TLR co-stimulation alone. 
 
TLR10 Suppresses B cell Activation Genes 
To further explore the effects of TLR10 ligation on B cell activity, we assessed the effect 
of TLR10 ligation on B cell signaling by high-throughput PCR Array of B cell activated genes.  In 
similar fashion with our proliferation studies, isolated peripheral B cells were pre-incubated with 
either isotype control or anti-TLR10 mAb in addition to a secondary anti-mouse antibody to 
enhance ligation of the TLR10 receptor as described in Materials and Methods.  Cells were then 
co-stimulated with anti-µ and CpG (a TLR9 agonist), and mRNA was collected after 24 hours of 
stimulation.  While no differences were detected in unstimulated cells incubated with either 
anti-TLR10 or isotype control antibodies (data not shown), cells in which TLR10 was activated 
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showed significant effects on signaling induced by BCR/TLR co-activation.  Of the 39 B cell 
activation genes tested in the PCR Array, 33 were suppressed by TLR10 (Fig 4.4). Interestingly, 
this attenuation was not limited to the genes that are positively regulated during activation, as 
several genes that are normally negatively regulated during stimulation were also less affected 
when TLR10 was engaged by antibody.  The three genes that exhibited the greatest degree of 
suppression are Chemokine Ligand 3 (CCL3), Chemokine Ligand 4 (CCL4) and Activation Induced 
Cytosine Deaminase (AICDA).  The chemokines CCL3 and CCL4, also known as MIP-1α and MIP-
1β respectively, are each potent chemoattractants secreted by lymphocytes and are involved in 
mediating cell migration and antibody secretion in the germinal center.  AICDA is necessary for 
both somatic hypermutation of the variable region of the BCR and also for CSR, events that both 
occur during clonal expansion in the germinal center.  These data show that antibody-mediated 
engagement of TLR10 is able to suppress the early stages of B cell activation.  
 
TLR10 Modulates B cell Cytokine Production 
To confirm that the suppression seen at the transcriptional level translates directly to 
the production of these chemokines, primary human B cell supernatants were analyzed for CCL4 
production after stimulation.  Here, we assessed a T-independent (TI) stimulus with the addition 
of αIgM and the TLR8 agonist R848 or heat-killed Staphylococcus aureus Cowan strain (SAC).  
After 24 hours, both conditions exhibited suppressed CCL4 production, supporting the RT-PCR 
data.  Interestingly, in accordance with the proliferation studies, the addition of an anti-CD40 
antibody to mimic T cell help did not rescue the suppression.  Furthermore, stimulation with 
either αIgM and αCD40 or αCD40 and R848 both exhibited a detectable suppression in the 
production of CCL4 (Fig. 4.5). This further suggests that the TLR10-mediated suppression is not 
limited to suppressing TLR agonists and may act to suppress B cell activation globally. 
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Suppression of Proximal B cell Signaling 
To gain further mechanistic insight into the ability of B cell-intrinsic TLR10 to suppress B 
cell activation, we studied the effect of TLR10 ligation on the immediate signaling events 
involved in B cell activation.  To answer that question, we examined the phosphorylation of the 
MAP kinases, ERK, JNK and p38 which are all involved in the TLR and CD40 signaling pathways.  
In addition to the MAP kinases, we also examined Syk and Akt, both of which are involved in the 
PI3K signaling pathway initiated by the BCR.  Primary human B cells were stimulated either 
through the BCR alone or with co-stimulation of either TLR7/8 or CD40 for 15 min and assessed 
for the phosphorylation status of the proteins listed above.  A modest suppressive effect was 
detected in all of the MAP kinases and also Akt regardless of the stimulus.  With the exception of 
phospho-JNK, TLR10 had the weakest effect on activation of the MAP kinases when the BCR was 
activated alone.  However, when the BCR was co-stimulated with either the TLR7/8 agonist 
R848, or anti-CD40, the suppressive effect of anti-TLR10 became more evident.  Compared to 
the isotype control condition, the greatest suppressive effect was observed in the 
phosphorylation of p38 upon co-stimulation of BCR and CD40.  Importantly, suppression was not 
detected in the phosphorylation of Syk, a proximal signaling adaptor emanating from the BCR, 
suggesting that TLR10 may act downstream of Syk signaling (Fig 4.6).  These results support the 
notion that TLR10 activation, for as little as 30 minutes before stimulation of the BCR and its co-
receptors, results in the suppression of immediate B cell signaling events.  Furthermore, these 
suppressive effects are not necessarily dependent on the activation of MyD88 signaling by B 
cell-intrinsic TLRs.  
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Generation of TLR10 Transgenic Mice (Performed by Dr. Xinyan Li) 
To determine the in vivo effect of TLR10 on B-cell activation, we generated a TLR10 
knock-in transgenic mouse that possesses the full-length human TLR10 gene behind its native 
promoter sequence (see Materials and Methods).  A total of three founder lines were 
established that exhibited detectable levels of TLR10 expression and the ability to pass the 
transgene onto their offspring.  Of the three founder lines, line 5-1 was selected for further 
functional assessment based on its intermediate level of TLR10 expression and large litter size.  
Line 5-1 exhibits RT-dependent expression of TLR10 messenger RNA in a variety of different 
tissues (Fig 4.7a).  Furthermore, splenic B cells exhibit both RT-dependent transcriptional 
expression and cell surface expression in transgenic mice compared to the non-transgenic 
control mice (Fig 4.7b,c). 
No physical differences were observed between non-transgenic and TLR10 transgenic 
mice.  Given the effect of TLR10 on human B cells, we wanted to assess whether TLR10 had any 
effect on B cell development.  To assess this, we examined different B cell sub-populations in 
several lymphoid tissues and could not find any differences in the ratio or abundance of the 
different B cell populations between transgenic and non-transgenic mice (Table 4.1).  
Additionally, we found that there was no difference in the immunoglobulin concentrations of 
the transgenic mice compared to the non-transgenic control mice (Fig. 4.8).  These findings 
show that TLR10 expression in mice does not cause detectable delays in homeostatic B cell 
development or antibody production. 
 
Suppression of ex vivo Transgenic B cell Activation (Performed by Dr. Xinyan Li and Nick Hess) 
To determine if TLR10 causes any functional differences on murine B cells, we pooled 
isolated splenic B cells from three transgenic and three non-transgenic control mice and 
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stimulated the cells in triplicate for 72 hours and measured IL-6 secretion.  Similar to primary 
human B cells, TLR10 transgenic mice exhibited suppressed IL-6 production in the presence of 
either BCR/TLR or BCR/CD40 stimulation (Fig. 4.9a).  To determine if the suppression detected 
results in global suppression of clonal expansion, isolated splenic B-cells were first pre-incubated 
with the fluorescent dye CFSE and then stimulated for 72 hours.  The CFSE dye allows for the 
monitoring of the number of cell divisions that each cell has undergone.  Again, regardless of the 
stimulus, fewer transgenic murine B cells underwent cell division as detected by the proportion 
of F1 cells (Fig 4.9b).  Importantly, these experiments were conducted without the addition of a 
TLR10 antibody to cross-link the receptor, suggesting that human TLR10 expression alone is 
sufficient to suppress murine B cell responses.  
 
Transgenic B cells are Suppressed in vivo (Performed by Dr. Xinyan Li) 
To examine the effect of TLR10 on B cell responses in vivo, we immunized the transgenic 
or non-transgenic control mice with the T-independent (TI) antigen LPS conjugated to the 
hapten nitrophenol (NP).  LPS is a known B cell mitogen in mice since murine B cells express 
TLR4.  One and two weeks after immunization, serum was collected from the mice and analyzed 
for the presence of NP-specific antibodies as a measure of the adaptive immune response to the 
antigen.  We analyzed the serum for the initial IgM antibody response and for the presence of 
class-switched antibodies such as IgG1, IgG2b, IgG2c and IgG3.  In all of the immunoglobulin 
isotypes analyzed, the transgenic mice exhibited a decreased level of NP-specific antibodies in 
their serum (Fig. 4.10).  This decrease was statistically significant for IgM and IgG3. 
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Transgenic TLR10 Suppression is B cell Intrinsic (Performed by Dr. Xinyan Li and Nick Hess) 
A potential problem with our transgenic mice is that TLR10 is expressed throughout the 
organism and on a variety of cell types.  We thus could not rule out the effect of TLR10 on other 
steps leading up to an adaptive immune response as the cause of our observed suppression of 
NP-specific antibodies in vivo.  Recent studies using adoptive transfer of MyD88-deficient B cells 
into µMT mice, as well as studies on isolated human B cells, have highlighted the importance of 
B cell-intrinsic TLR activation in a robust humoral response (Barr et al. 2009; He, Qiao, Cerutti 
2004; Meyer-Bahlburg, Khim, Rawlings 2007; Pasare and Medzhitov 2005).  To resolve this 
question, we isolated pooled splenic B cells from either the transgenic or non-transgenic control 
mice, and transferred them intravenously into μMT mice.  The μMT mice lack the μ gene 
required for the proper development of functional B cells, and as a result do not possess any 
mature B cell populations.  After transfer of the B cells, we immunized the mice with NP-LPS to 
assess their ability to respond to a TI antigen.  Similar to immunization in the transgenic mouse, 
all the immunoglobulin isotypes assayed in the μMT mice reconstituted with transgenic TLR10 B 
cells exhibited suppressed NP-specific antibodies levels (Fig. 4.11).  Since adoptive transfer of B 
cells results in lower induction of all NP-specific antibody classes, only IgM was statistically 
different between transgenic and non-transgenic reconstituted mice. 
Lastly, to address if B cells are suppressed in the presence of T cell help, we immunized 
μMT mice reconstituted with either TLR10 transgenic or non-transgenic B cells with the T-
dependent (TD) antigen NP-CGG (chicken-gamma globulin) and LPS to boost the immune 
reaction.  As before, all immunoglobulin isotypes assayed in μMT mice reconstituted with 
transgenic B cells exhibited suppressed NP-specific antibody levels compared to non-transgenic 
controls (Fig. 4.12).  This TLR10-induced decrease was statistically significant across a variety of 
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immunoglobulin isotypes.  These data support the ex vivo data using human B cells and show 
that TLR10 is a B cell-intrinsic suppressor of both TI and TD B cell activation. 
 
Discussion 
The TLR10 gene was first cloned in 2001 and found to be expressed in lymphoid tissue, a 
unique expression pattern among TLRs (Chuang and Ulevitch 2001).  Subsequent investigations 
have revealed preferential expression of the TLR10 message in B cells, with enhanced 
expression in circulating memory B cells.  In studies described in Chapter Three, we further 
validated these findings at the surface protein level and also showed that TLR10 expression is 
suppressed along progressive stages of B cell activation at the germinal center.  Our lab has also 
published findings revealing the capacity of the TLR10 extracellular domain to heterodimerize 
with that of TLR2 to recognize triacylated lipopeptides, similar to its close homologue, TLR1; 
however, these studies were unable to detect any subsequent signaling outputs (Guan et al. 
2010).  Since that time, investigators have reported the possible role of TLR10 in mediating the 
innate immune inflammatory responses to live Listeria monocytogenes as well as influenza virus 
infection (Lee et al. 2014; Regan et al. 2013).  Conversely, we and others have shown evidence 
supporting the notion that TLR10 is a negative regulator of MyD88, as well as TRIF signaling 
(Jiang et al. 2016; Oosting et al. 2014; Stappers et al. 2015).  While a preponderance of 
polymorphism studies have linked TLR10 to a variety of diseases including skin infections, 
Helicobacter pylori, tuberculosis, asthma, and nasopharyngeal carcinoma, the precise 
physiological function of TLR10 remains to be elucidated.  To this end, we investigated the role 
of TLR10 activation in the context of B cell biology, a setting where previous studies have shown 
TLR10 to be preferentially expressed.  Our findings largely support the hypothesis that TLR10 
acts as a suppressor of the adaptive humoral immune responses of B cells in vivo.  
92 
 
Since the discovery of TLRs, much of the focus has been on how TLRs positively regulate 
inflammation, although more recently, research has focused on the negative regulation of TLR 
signaling (Kondo, Kawai, Akira 2012).  Two TIR domain-containing adaptors, SIGIRR and ST2, 
have been shown to negatively regulate TLR signaling, likely by sequestering the proximal 
adaptor MyD88 or other signaling molecules in the pathway (Brint et al. 2004; Wald et al. 2003).  
In similar fashion, overexpression of TLR10 has been shown to abrogate signaling from MyD88 
as well as TRIF (Jiang et al. 2016).  While the mechanism for TLR10-mediated suppression is not 
yet fully understood, it would appear that given the ability of TLR10 to suppress B cell signaling 
emanating from BCR/CD40 stimulation alone, regulation occurs through an as yet unappreciated 
signaling pathway that creates a broad suppressive effect on B cell responses.  Additionally, the 
observation that TLR10 is not under convergent evolution, has numerous nonsynonymous 
mutations in its TIR domain and is able to form a stable homodimer may allow TLR10 to recruit 
novel TIR domain-containing proteins (Mikami et al. 2012; Nyman et al. 2008).  Much of TLR 
biology focuses on the five well-studied TIR-domain-containing proteins MyD88, MAL, TRIF, 
TRAM and SARM; however, there certainly exist additional TIR domain adaptors that remain 
understudied or undiscovered (Kawasaki and Kawai 2014).  One such example is the protein B 
cell adaptor for PI3K (BCAP), which is a novel, TIR-domain-containing, protein that has been 
linked to TLR and PI3K signaling.  More importantly, a BCAP knockout mouse was shown to have 
elevated levels of inflammation in response to a S. typhimurium infection (Troutman et al. 
2012).  The ability of TLR10 to actively suppress a broad range of signaling pathways makes it 
likely that TLR10 is not just a sequestering signaling mediator, but is more likely actively 
recruiting a novel signaling protein to mediate TLR10-dependent suppression.   
In the context of B cells, there is a growing body of evidence for a synergistic 
relationship between the BCR, TLRs and TNF-family receptors in the B cell signaling cascade.  
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Several key mediators of each pathway have been shown to be important in the regulation of 
the other parallel pathways.  Specifically, interactions between common adaptors protein kinase 
D, Btk, TRAF5 and Syk have been shown to create a synergistic signaling network that brings 
together multiple input signals resulting in an array of cellular responses (Buchta and Bishop 
2014; Haxhinasto and Bishop 2003; Kenny et al. 2013; Ying et al. 2011).  It is very possible that 
the broad suppressive effect of TLR10 may be due to its interaction with adaptor proteins 
common to these pathways, resulting in the suppression of more than one pathway 
simultaneously.  Additionally, recent reports have revealed the requirement of the receptor 
TACI in the production of switched antibodies.  This is best evidenced in the observation that 
10% of patients with combined variable immune deficiency (CVID) have mutations in the TACI 
gene.  These individuals present with an impaired ability to produce antigen-specific antibody, 
including IgM and switched isotypes (Lobito et al. 2011).  Recently, investigators have reported 
that the TACI system interacts with the proximal adaptor MyD88 (He et al. 2010), whose 
signaling capacity has been shown in our preliminary studies to be potently suppressed by 
TLR10.  A logical mechanism of the modulatory function of TLR10 in B cells may be manifested in 
its ability to inhibit the T cell-independent induction of antibody isotype switching by the TACI 
system. 
The importance of B cell-intrinsic MyD88 signaling was first highlighted in a landmark 
study using adoptive transfer of MyD88-deficient B cells into µMT mice (Pasare and Medzhitov 
2005).  Here, investigators reported that robust antigen-specific antibody responses not only to 
TI antigens, but also to TD antigens required a third signal from B cell-intrinsic TLRs.  These 
studies, however, were not met without controversy, as subsequent studies by others reported 
that MyD88/TRIF double-deficient mice generated robust antibody responses to the TD antigen 
trinitrophenol-haemyocyanin (Nemazee et al. 2006).  A third study using the TD antigen NP-CGG 
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showed that µMT mice reconstituted with either wild-type MyD88 or knockout B cells exhibited 
similar increases in NP-specific antibody titers, suggesting a dispensable role for B cell-intrinsic 
TLRs in the humoral response; however, the authors highlighted the finding that B cell-intrinsic 
TLR responses are up-regulated during the germinal center reaction and significantly promote 
antigen-specific IgM production in association with TLR ligands (Meyer-Bahlburg, Khim, Rawlings 
2007).  These studies have profound implications in the design of vaccines and whether TLR 
recruitment is required for vaccine efficacy and a robust humoral memory.  In our studies, we 
observed that TLR10 suppresses humoral responses in the context of TI antigen stimulation, as 
well as responses to the TD antigen NP-CGG.  This suggests that even in a setting where B cell-
intrinsic MyD88 has a questionable role, TLR10 maintains a broad suppressive effect on B cell 
responses.  Additionally, our findings raise the interesting possibility that blockade of TLR10 has 
the potential to enhance the induction of a successful humoral response in the context of 
vaccine design. 
While we have shown here that TLR10 is a suppressor of B cell immune responses, 
several other studies have shown divergent functions for TLR10.  Data presented by our group 
and Oosting et al. both present TLR10 as an anti-inflammatory receptor and are supported by 
complementary human and transgenic mouse studies that show similar results.  Interestingly, 
both Regan et al. and Lee et al. were able to show a pro-inflammatory role for TLR10, but only in 
the context of live Listeria monocytogenes or flu virus (H5N1) infections.  It is possible that our 
opposing studies may actually represent different roles in TLR10 biology that has yet to be fully 
understood. 
TLR10 remains a vastly understudied TLR that for many years was believed to have no 
biological function.  In these studies, we provide evidence to support the expression of TLR10 
within human B cells where it can, through antibody-mediated crosslinking, suppress the 
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activation of human B cells.  Furthermore, we have shown that the TLR10 machinery is 
conserved across mammals by creating a knock-in mouse model that expresses the full-length 
human TLR10 under its native promoter which has the ability to suppress murine B cell 
activation.  Importantly, the ability of TLR10 to suppress B cells in this context occurs 
independently of the addition of any activating ligand.  One possible explanation may be that 
the heterologous expression of TLR10 constitutively induces activation of a suppressive signaling 
pathway in the mouse.  We have also seen that heterologous overexpression of TLR10 under a 
constitutive promoter in stable cell lines and transient transfection experiments induces an 
agonist-independent suppression of immune signaling (Jiang et al. 2016).  In our transgenic 
mouse model, however, we also cannot rule out the possibility of a natural agonist found in the 
mouse that induces TLR10 activation.  In any case, the natural ligand for TLR10 remains an 
important unanswered question that remains to be resolved. 
Conclusions from these studies provide numerous avenues of further investigation with 
regards to TLR10 biology.  The role of TLR10 in the suppression of B cell proliferative responses 
as well as its specific expression in the B cell lineage bodes well for its potential as a therapeutic 
target for numerous B cell malignancies stemming from mutations resulting in aberrant 
proliferative control.  Additionally, the ability of TLR10 to suppress immediate signaling events 
involved in B cell activation implies a physiological role for this receptor in the maintenance of B 
cell homeostasis and the control of nonspecific activation in the context of rheumatic diseases 
(Joosten et al. 2016).  Indeed, in autoimmune pathologies such as systemic lupus 
erythematosus, inappropriate activation of B cells against self DNA antigens results in the 
formation and deposition of immune complexes that result in vasculitis and end organ damage.  
The potential for targeting TLR10 and harnessing its natural role in suppression of B cell 
responses in this context is an exciting area of future research.   
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Figures and Tables 
 
 
 
  
 
Figure 4.1. TLR10 is Expressed on the Plasma Membrane of B Lymphocytes. (A) TLR10 staining 
of gated lymphocytes from whole blood using a triple labeling procedure. (B) Dot plots of 
lymphocytes co-stained with either CD19 or CD3 along with TLR10. 
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Figure 4.2. TLR10 mAb Inhibits SAC-induced B cell Proliferation.  Human peripheral B cells were 
isolated by negative selection from PBMC.  B cells were pre-incubated with media alone, IgG1, 
or anti-TLR10 mAb with or without secondary goat anti-mouse F(ab)’2 (2nd) for 1 hour as 
indicated.  Cells were then stimulated with Staphylococcus aureus Cowan strain (SAC), a 
common B cell mitogen, for four days.  Proliferation was measured by BrdU incorporation.  Error 
bars represent triplicate samples. 
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Figure 4.3. Primary Human B Lymphocyte Activation is Suppressed by a TLR10 mAb.  Human B 
lymphocytes were isolated from 6 different donors and stimulated as indicated.  After 72 hr, 
BrdU was added and the cells assayed at 96 hr for BrdU incorporation by ELISA. To compare data 
from 6 individual assays, absorbance values from 6 individual donors were normalized to the 
maximum average absorbance values observed for each donor in the anti-IgM + R848 condition.  
**p < 0.05; ***p < 0.01 
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Figure 4.4. Genes Regulated by TLR10. Human B lymphocytes were isolated from primary 
peripheral blood by negative selection and pre-incubated with either IgG1 or TLR10 ab for 30 
min prior to stimulation with αIgM and CpG. After 24 hr of stimulation, RNA was isolated and 
assayed by a PCR superarray assay for B cell activation markers. Bars represent fold expression 
compared to unstimulated cells. On the right is the list of genes regulated by TLR10 in primary 
human B cells in order of largest positive fold stimulation to largest negative fold stimulation 
relative to an unstimulated control group.  
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Figure 4.5. TLR10 mAb Inhibits Production of MIP-1β from Peripheral Blood B cells.  Human 
peripheral blood B cells were isolated by negative selection and were pre-incubated with either 
IgG1 isotype control or anti-TLR10 ab, as indicated.  30 min later cells were stimulated with the 
indicated agonists.  After 24 hr, cell-free supernatants were collected and assayed using a 
human MIP-1β paired-antibody ELISA.  Error bars represent the standard deviation of triplicate 
samples.  *p < 0.1; **p < 0.05; ***p < 0.01 
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Figure 4.6. TLR10 Antibody-Mediated Engagement Suppresses Proximal BCR Signaling in 
Primary B lymphocytes.  Human B lymphocytes were isolated from primary tonsillar tissue by 
homogenization, density centrifugation and a B-cell specific negative selection antibody cocktail. 
B cells were pre-incubated for 30 min with either IgG1 or anti-TLR10 and then stimulated with 
the indicated agonists for 15 min after which cell lysates were collected. Western blots were 
performed on the indicated targets using phospho-specific antibodies.  Actin is shown as a 
loading control.  The experiment is representative of at least three individual experiments. 
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Figure 4.7. TLR10 Transgenic Mice Stably Expresses Human TLR10 on B cells.  (A) The indicated 
organs from transgenic mice were collected and homogenized in Trizol with a Dounce 
homogenizer. RNA was purified and TLR10 expression was assessed via PCR with and without 
reverse transcriptase (RT) as indicated. (B) Transgenic and non-transgenic murine RNA was 
isolated from splenoctyes and assayed as in (a) for TLR10 expression.  (C) Murine splenocytes 
were triple labeled for TLR10 and the B cells markers B220 and IgM.  Cells expressing B220 and 
IgM were gated and analyzed for TLR10 expression.  Bar graph represents the ΔMFI and 
standard deviation from 3 different mice per group. 
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Table 4.1. TLR10 Transgenic Mice Show No Developmental Differences in B cell Populations.  
Nc & Tg mice were assayed for developmental deformities in B-cell populations.  B cell sub-types 
were differentiated by indicated markers and compartments.  Percent positive cells represent 
an average of at least two mice. 
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Figure 4.8. TLR10 Transgenic Mice Show No Developmental Differences in Isotype Specific 
Antibody Production.  Blood collected from six non-transgenic and TLR10 transgenic mice was 
assayed for gross abnormalities in isotype specific antibody production via an isotype specific 
multiplex kit.  No significant developmental differences was detected. 
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Figure 4.9. TLR10 Transgenic Splenic B cell Populations Exhibit Suppressed Cytokine 
Production & Proliferative Capacity.  Murine B cells were pre-incubated with CFSE and 
stimulated with the indicated agonists.  After 3 days, cell-free supernatants were assayed for IL-
6 secretion (A) and cells were analyzed for proliferation by flow cytometry (B). 
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Figure 4.10. TLR10 Transgenic Mice Exhibit Suppressed Type 1 T-Independent (TI) Antibody 
Responses.  Non-transgenic control (Nc) and TLR10-transgenic (Tg) age-matched male mice 
were immunized with 10 μg of NP-LPS through i.p. injection.  Serum was collected one day prior 
to immunization and seven and fourteen days after immunization.  Serum was subsequently 
assayed for NP-specific antibody responses by ELISA.  Arbitrary units represent antibody levels 
after normalization to pre-immunized mice.  Statistics performed using GraphPad Prism 
software. **p < 0.05 
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Figure 4.11. The Suppression of Type I T-Independent (TI) Antibody Responses in TLR10 
Transgenic Mice is B cell Intrinsic.  Five Nc and Tg age-matched male mice were euthanized and 
splenic B lymphocytes isolated by negative selection.  Eight age-matched male μMT mice (that 
lack functionally mature B lymphocytes) were injected i.v. with approximately 2 x 107 of the 
pooled B lymphocytes.  One day post transfer, mice were immunized with 20 μg of NP-LPS by 
i.p. injection.  Blood was collected and serum assayed for NP-specific antibody responses as 
described in 4.10.  *p < 0.1; ***p < 0.01 
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Figure 4.12. The Suppression of T-Dependent (TD) Antibody Responses in TLR10 Transgenic 
Mice is B cell Intrinsic.  B cell transfer was completed as described in Figure 8. One day post 
transfer, mice were immunized with 100 μg of NP-CGG + 5 μg of LPS by i.p. injection. Blood was 
collected and serum assayed for NP-specific antibody responses as described in Figure 4.10.  *p 
< 0.1; **p < 0.05; ***p < 0.01 
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CHAPTER 5 
CONCLUSION 
Summary 
The dissertation research presented here seeks to define the physiological function of a 
receptor protein, TLR10, with no previously known signaling function.  This work has revealed a 
potential role for TLR10 as a negative regulator of immune signaling, with specific inhibitory 
effects on both the proximal TLR signaling adaptors MyD88 and TRIF, as well as global 
suppression of B cell activation emanating from the BCR and its co-receptors.  In this final 
chapter, I will summarize the major findings from our efforts to elucidate the function of TLR10 
described in Chapter Two through Chapter Four, elaborate on the significance of these findings 
for the field, and highlight remaining questions and future directions that may be worthy 
avenues of pursuit to fully understand TLR10 biology. 
In Chapter Two of this thesis presentation, I described a novel function for TLR10 as a 
negative regulator of pro-inflammatory TLR signaling.  Two major challenges to the study of 
TLR10 up until this point were the lack of a functional TLR10 gene in mice and the lack of 
previous success in knocking down endogenous TLR10 using traditional siRNA silencing 
techniques.  My approach was thus to use heterologous overexpression systems to study the 
effect of TLR10 expression on cells that do not normally express detectable TLR10.  
Notwithstanding the limitations of such an approach, my findings using stable cell lines and 
transient transfection techniques revealed the ability of TLR10 to significantly diminish pro-
inflammatory signaling and cytokine production.  Additionally, using a transient overexpression 
approach, I observed that TLR10 suppressed pro-inflammatory signaling from both the MyD88-
dependent and TRIF-dependent signaling pathways.  These findings were further corroborated 
with parallel studies in a TLR10 transgenic mouse model created by Dr. Xinyan Li.  Her findings 
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using this system recapitulated my findings in human cells, providing us with an important clue 
regarding the capacity of TLR10 to suppress immune signaling. 
In Chapter Three of this dissertation, I presented key findings from my efforts to explore 
the expression pattern of endogenous human TLR10 with the hopes of gaining further insight 
into its physiological function.  I highlighted extensive work by Dr. Yue Guan in the lab who 
successfully generated a monoclonal antibody specific for TLR10 and showed that TLR10 is 
expressed on the surface of CD19+ B lymphocytes in peripheral blood.  In light of this work, I 
sought to explore donor to donor variation of TLR10 expression in ten individual donors.  It was 
found that surface expression of TLR10 varied little from individual to individual, with TLR10 
surface expression consistently confined to the lymphocyte population in peripheral blood, and 
with specific correlation with the B cell marker CD19.  I also showed that TLR10 surface protein 
expression was increased in CD27 positive peripheral B cells, thus supporting previously 
published studies at the mRNA level suggesting increased TLR10 transcript in circulating memory 
B cells.  These studies further spurred my investigation into the expression of TLR10 along the B 
cell lineage.  To this end, TLR10 expression was assessed in bone marrow mononuclear cells of 
five individual donors, which allowed us to evaluate TLR10 expression during B cell 
hematopoiesis.  It was discovered that TLR10 expression again strongly correlated with CD19 
expression in this cell population, with surface expression observed from the pro-B cell to the 
mature circulating B cell stage but with lack of expression in terminally differentiated plasma 
cells.  Lastly, we wished to study TLR10 expression in the context of B cell activation in the 
germinal center, as previous studies had shown that TLR expression may be tightly regulated 
during this process.  With the help of Nicholas Hess and Usmaan Shah in the lab, our studies 
provided a surprising finding that revealed progressively diminished TLR10 expression as B cells 
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enter the germinal center reaction, lending support to the notion that TLR10 has an important 
role in B cell function. 
The investigation of TLR10 function in the context of B cell activation presented in 
Chapter Four represents a logical extension of our findings in Chapters Two and Three.  Given 
TLR10’s unique expression pattern and closely regulated surface receptor expression in the B 
cell lineage, we rationalized that TLR10 likely played a physiologically relevant function in the 
context of B cell biology.  Indeed, the role for B cell-intrinsic TLR function in the immune 
response and in autoimmune pathologies, as well as new insight into the role of MyD88 
signaling in the context of B cell malignancies, provided an exciting area in which to explore the 
potential regulatory effects of TLR10 in B cells (Booth et al. 2010; Gerondakis, Grumont, 
Banerjee 2007; Green and Marshak-Rothstein 2011; Ngo et al. 2011).  My studies relied heavily 
on the capacity of our anti-TLR10 monoclonal antibodies to ligate TLR10 and serve as an 
activating ligand for this receptor, a technique widely used in the field that has been 
instrumental in elucidating the function of surface B cell receptors such as CD20, CD40, and 
RP105 (Clark 1990; Roshak et al. 1999; Tedder and Engel 1994).  In my initial studies, I 
discovered that activation of cell surface TLR10 diminished the proliferative response of 
peripheral blood B lymphocytes following stimulation by the B cell mitogen SAC.  This effect was 
further enhanced when I added a secondary F(ab)’2 fragment to enhance the crosslinking effect, 
suggesting homotypic dimerization or receptor clustering as a mechanism for TLR10 activation. 
Armed with this exciting discovery, I further investigated the effects of TLR10 activation 
on other B cell stimuli.  These experiments led to the unexpected discovery that TLR10 
suppression was not necessarily specific to B cell-intrinsic TLR signaling, but rather had global 
effects on B cell responses to stimulation of the BCR and CD40 alone, suggesting an effect on 
responses to both T-independent and T-dependent B cell antigens.  I next performed a gene 
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array analysis of B cell signaling transcripts activated by BCR and TLR co-stimulation.  I 
discovered that TLR10 activation had profound suppressive effects on a majority of the 
transcriptional responses to B cell activation.  These findings were further validated at the 
protein level, as TLR10 was shown to significantly suppress MIP-1β production.  Concurrently 
with these studies, again with a close collaborative relationship with Dr. Xinyan Li and Nicholas 
Hess, a transgenic mouse line expressing human TLR10 under its native promoter was created, 
allowing us to assess broad physiological effects of heterologous TLR10 expression.  We 
discovered that, in accordance with my findings in human B cells, transgenic mouse splenoctyes 
showed reduced proliferative and cytokine responses in addition to profoundly diminished 
serum antibody responses to both T-dependent and T-independent antigens.  Importantly, 
these effects were later shown to be B cell-intrinsic by classic adoptive transfer experiments 
performed by Dr. Xinyan Li and Nicholas Hess.  This work together provide convincing evidence 
that TLR10 is a suppressive member of the TLR family that functions in the context of B cell 
physiology. 
 
Significance 
Since the landmark work of the likes of Jules Hoffman, Charles Janeway, Ruslan 
Medzhitov, Bruce Beutler and many others in the late 1990s, the TLR field has exploded with an 
ever-increasing knowledge base on TLR ligand recognition, signaling function, and impact on 
human disease.  The human TLRs 1 – 9 have been extensively studied with well-established 
ligand recognition and structure-function studies that have given the field tremendous insight 
into the critical role of TLRs not only in initiating innate immunity, but also in mounting a 
tailored and specific adaptive immune response.  Despite this extensive work, however, TLR10 
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remains an orphan receptor with no established ligand or signaling function.  The work 
presented here partially fills this knowledge gap. 
My studies showing the suppressive effect of TLR10 presented in Chapter Two were the 
first evidence that TLR10 is a suppressive TLR.  Using a technique similar to that employed by 
Janeway and Medzhitov in 1997 in the first assessment of human TLR signaling (Janeway, 
Medzhitov, Preston-Hurlburt 1997), we were the first to find that constitutively active CD4-
TLR10 chimeras not only failed to produce a pro-inflammatory output, but in fact had a 
dominant negative effect on MyD88 and TRIF signaling.  While precedence for such TIR-domain 
containing regulatory adaptor molecules exist, TLR10 is the first member of the TLR family 
known to play a regulatory or anti-inflammatory role.  Other laboratories have also found a 
suppressive effect by TLR10, including work by Oosting et al., which found that TLR10 
suppresses pro-inflammatory cytokine production induced by TLR2 ligands (Oosting et al. 2014).  
Importantly, our findings extend the suppressive effects of TLR10 to both the MyD88 and TRIF 
pathways.  These results bear striking similarity to other TLR-IL-1R superfamily members with 
suppressive function, such as ST2 and SIGIRR, TIR-domain containing membrane proteins known 
to specifically inhibit IL-1R signaling by an as yet unknown mechanism (Brint et al. 2004; Wald et 
al. 2003). 
Additionally, the results reported in Chapter Three represented the first assessment of 
endogenous surface TLR10 expression using a monoclonal antibody reagent created in our 
laboratory.  Since the discovery of the TLR10 gene in 2001 (Chuang and Ulevitch 2001), TLR10 
expression studies have relied almost exclusively on RT-PCR techniques with little information 
on protein expression levels due the lack of a reliable antibody.  Although much of the results I 
presented validated previous findings that TLR10 transcripts were preferentially present in B 
cells, we were able to assess donor to donor variations in TLR10 surface expression as well as 
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gain further insight into the transient regulation of TLR10 expression during the germinal center 
reaction that was previously unappreciated.  These studies provided the impetus and rationale 
for our continued work in studying TLR10 function in the context of B lymphocyte biology. 
The studies presented in Chapter Four highlight a previously unrecognized capacity for 
TLR10 in the regulation of B cell responses.  Various TLR agonists have already been shown to 
induce a variety of B cell responses (Pone 2016).  My initial studies were the first to show that 
activation of TLR10, through antibody engagement, suppressed B cell responses not only to TLR 
co-stimulation, but also to BCR and CD40 co-stimulation alone.  These results highlighted the 
broad suppressive effects of TLR10, likely due to its interaction with an as yet unknown adaptor 
shared with multiple signaling pathways.  The significance and validity of these findings were 
also greatly enhanced by our transgenic TLR10 mouse model, which enabled us to recognize 
broad suppressive effects on antigen-specific serum antibody responses, as well as adoptive 
transfer experiments showing that the effect of TLR10 was B cell-intrinsic.  These studies provide 
the first evidence that TLR10 regulates antigen-specific B lymphocyte responses and antibody 
production. 
 
Future Directions 
Given the suppressive role of TLR10, its highly regulated expression pattern in the B cell 
lineage, and its capacity to globally suppress B cell responses to both T-independent and T-
dependent antigens, the work presented in this thesis opens the door to several lines of future 
investigation.  For example, important questions remain regarding the precise mechanism of 
TLR10 suppression.  Through co-immunoprecipitation experiments, we have previously shown 
that TLR10 interacts with MyD88 along with TLR2 (Guan et al. 2010), suggesting that TLR10 may 
suppress activation by simply outcompeting other TLRs for MyD88 in a non-productive fashion.  
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However, TLR10 exhibits a dominant negative effect even in the context of MyD88 
overexpression, suggesting that TLR10 signaling induces the activity of a separate as yet 
unknown regulatory pathway that actively inhibits immune signaling.  Importantly, unlike the 
two other IL-1R family TIR-domain containing suppressor molecules ST2 and SIGIRR, TLR10 was 
shown to suppress TRIF signaling and the production of type I interferon, further indicating the 
engagement of an actively suppressive signaling pathway.  Such a mechanism would also better 
explain the broad suppressive effect of TLR10 on B cell signaling, where numerous signaling 
pathways emanating from the BCR and its co-receptors engage in cross-talk culminating in a 
multitude of B cell fates.  Notably, our analyses suggest that TLR10 affects early signaling events 
such as the phosphorylation of Syk and the MAPKs immediately downstream of the BCR.  The 
precise signaling pathway(s) utilized by TLR10 to achieve its suppressive effects remains to be 
determined and is an interesting and important avenue of pursuit.  In the case of ST2, 
researchers observed strong TIR-domain dependent interactions with MyD88, but not TRIF, 
leading them to conclude that it acts via non-productive sequestration of MyD88.  In the case of 
SIGIRR, researchers observed an IL-1-dependent interaction of endogenous SIGIRR with the 
signaling molecules IRAK and TRAF6, suggesting that it may exert its regulatory effects through 
these adaptors.  In the case of TLR10, we observed strong suppressive effects on the proximal 
adaptors MyD88 and TRIF.  However, signaling induced by constitutive activation of IRAK and 
TRAF6 were unaffected by TLR10 overexpression, indicating that it acts upstream of these 
signaling components (unpublished data).  Further mechanistic insight into TLR10 signaling may 
provide opportunities to discover novel anti-inflammatory pathways with great potential for 
therapeutic targeting. 
Another important area that remains open to speculation is the relationship between 
the regulation of TLR10 surface expression and its suppressive function in the context of the 
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germinal center reaction.  We were surprised to find that TLR10 surface expression is tightly 
controlled through each stage of B cell activation.  Given its suppressive role, one could 
speculate that as B cells undergo activation to the plasmablast stage, progressively less 
inhibitory signal is required as terminal differentiation into antibody-producing plasma cells 
occurs.  Left unresolved, however, is the high level of TLR10 expression found in circulating 
CD27+ memory B cells.  Such cells are known to proliferate with TLR signaling alone without the 
need for engagement of the BCR (Bernasconi, Onai, Lanzavecchia 2003; Chiron et al. 2008), so 
one would imagine that suppressive receptors such as TLR10 would be downregulated.  On the 
other hand it is also possible that TLR10 expression is increased in this population precisely to 
serve the purpose of modulating nonspecific activation of this highly sensitized B cell 
population.  Further work to define the effects of TLR10 in this specific context is required to 
understand its role. 
Perhaps the most important unresolved question lies in the natural ligand for TLR10.  
While previous studies in the lab have revealed the capacity of TLR10 to heterodimerize with 
TLR2 to recognize triacylated lipopeptides (Guan et al. 2010), my studies would suggest that the 
inhibitory action of TLR10 occurs independently of TLR2, as CD4-TLR10 homodimers alone 
strongly inhibit MyD88 and TRIF signaling, and antibody-mediated engagement of TLR10 
activates suppression.  Without the possibility of a knock-out mouse model, further study of 
TLR10 would necessarily rely on another animal model, such as a knock-out rat, or the silencing 
or knock-out of TLR10 in human B lymphocytes.  While this has historically remained a large 
technical challenge, the advent of systems such as CRISPR-Cas9 to create genomic knock-outs in 
human cells provides promising avenues of future research.  Knowledge of the suppressive 
responses induced by TLR10 provided in this current work will also hopefully provide the 
experimental outputs for future studies investigating TLR10’s natural ligand.   
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This functional information also allows us to speculate on possible ligands worthy of 
further research.  For example, numerous endogenous signals are known to be anti-
inflammatory or signal the resolution of the immune response and the restoration of tissue 
homeostasis.  IL-10 and TGF-β are two such regulatory cytokines that have been extensively 
studied and known to be integral in the control of inflammation and the initiation of tissue 
repair.  IL-33 is a relatively newly appreciated relative of IL-1 which was found to be an anti-
inflammatory cytokine that suppresses Th1 responses in favor of Th2-associated cytokine 
production through its interaction with ST2 (Schmitz et al. 2005).  Another anti-inflammatory 
relative of IL-1 is IL-37, a cytokine whose precise mechanism and receptor is yet to be 
elucidated, but which shows broad suppressive effects on immune signaling (Nold et al. 2010).  
A possible interaction between these molecules and TLR10 certainly deserves further 
investigation.   
Other endogenous ligands that fall under the broad class of so-called danger-associated 
molecular patters (DAMPs) are also worthy of consideration as TLR10 agonists.  Of particular 
interest are rapidly generated lipid mediators that are active during the resolution phase of 
inflammation, including lipoxins and the ω3-unsaturated fatty acid-derivatives termed resolvins 
and protectins (Serhan, Chiang, Van Dyke 2008).  These molecules are actively synthesized and 
act by both promoting the uptake and clearance of apoptotic cells as well as inhibiting the 
production of pro-inflammatory cytokines.  We have shown that TLR10 has the capacity to 
recognize lipidated components of the bacterial cell wall with TLR2 (Guan et al. 2010), so the 
capacity of TLR10 to recognize lipid mediators known to be anti-inflammatory remains an 
intriguing possibility. 
Lastly, the search for an exogenous ligand for TLR10 should begin with a thorough 
investigation of helminth-derived molecules given the suppressive function of TLR10, as well as 
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numerous studies implicating TLR10 polymorphisms in the pathogenesis of asthma (Heinzmann 
et al. 2010; Kormann et al. 2008; Lazarus et al. 2004; Phipps et al. 2007).  Longstanding 
paradigms in the field of asthma and allergy such as the Hygiene Hypothesis and the Old Friends 
Hypothesis proposed by Graham Rook strongly implicate the importance of helminthic exposure 
in the modulation of autoimmune disease.  Via exposure to excretory-secretory (ES) products, 
helminthic infection is known to have immunomodulatory sequelae that result in a Th2 
response characterized by the expansion of Th2 cells, alternatively activated macrophages, 
upregulation of Tregs, production of polyclonal IgE by B cells, and consequent suppression of the 
Th1/Th17 response (Shepherd et al. 2015).  Immunomodulatory components of helminths make 
up a complex mixture of proteins, peptides, glycans, lipids, and small organic molecules that 
could possibly engage TLR10 to inhibit pro-inflammatory signaling.  Similar to ST2, this 
engagement may be a mechanism by which helminth-derived ligands modulate the immune 
system to favor the Th2 response. 
The suppressive potential and expression pattern of TLR10 make it a potential 
therapeutic target in the context of B cell malignancies as well as autoimmune disease.  TLR 
signaling has been strongly implicated in the progression of multiple myeloma (MM) and chronic 
lymphocytic leukemia (CLL), and specific oncogenic mutations in the TIR domain of MyD88 are 
found in 91% of lymphoplasmacytic lymphomas, 29% of a particularly malignant subtype of 
diffuse large B cell lymphoma, 9% of gastric MALT lymphomas, and 13% of splenic marginal zone 
lymphomas (Isaza-Correa et al. 2014).  Specifically, stimulation by various TLR agonists have 
been shown to directly induce proliferation of MM and CLL samples (Bohnhorst et al. 2006; 
Jahrsdorfer 2005), while the activating mutation L265P in MyD88 is known to trigger IRAK-
mediated NF-κB signaling and is recognized as a driver mutation in an IgM-secreting form of 
lymphoplasmacytic lymphoma termed Waldenstrom’s macroglobulinemia.  Additionally, TLRs 
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have been shown to play a prominent role in the pathogenesis of autoimmune diseases such as 
systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis (Gianchecchi and 
Fierabracci 2015).  Given the suppressive capability of TLR10 and its specific expression on B 
cells, targeting this molecule would serve as a rational model for modulating the aberrant 
proliferation of malignant B cells or attenuating B cell activation in the context of autoimmune 
disease.  Further knowledge of TLR10 biology would certainly aid in realizing this therapeutic 
potential.   
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